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1. Introduction 
1.1 TGF-β superfamily and BMP subfamily 
 
The transforming growth factor-β (TGF-β) superfamily forms a group of structurally 
related cytokines. According to similarities of amino acid sequences, the TGF-β 
superfamily can be classified into bone morphogenetic proteins (BMPs), growth and 
differentiation factors (GDFs), TGF-βs, activins and others (Fig. 1.1) (1, 2). The 
TGF-β superfamily of growth factors comprises seven genes in Drosophila 
melanogaster and at least 30 genes in mammals, including 3 TGF-β isoforms, 4 
activin β-chains, the protein nodel, 10 bone morphogenetic proteins (BMPs) and 11 
growth and differentiation factors (GDFs) (3). These proteins are found in almost all 
cell types and are involved in numerous cellular processes, including bone and joint 
development, cell proliferation and differentiation, and dorsal/ventral patterning of the 
animal embryo, trauma and wound repair (4, 5).  
 
BMP proteins were first isolated on the basis of their bone-inducing activity in 
mammalian tissues and were therefore named as BMPs (4). BMPs account for most of 
the TGF-β superfamily of peptides, and the proteins display extensive conservation 
among species (6). BMPs were found to play crucial roles in embryogenesis and 
organogenesis during vertebrate and invertebrate development (7). During embryonic 
life, BMPs regulate neurogenesis and hematopoiesis, and induce somite formation. 
BMPs regulate multiple cellular processes such as cell proliferation and 
differentiation, apoptosis and pattern formation and tissue specification during 
embryonic development (7, 8). After birth, BMPs play a role in the maintenance of 
bone mass. They induce the differentiation of marrow stromal cells toward the 
osteoblastic lineage, therefore increasing the pool of mature bone forming cells, and 
enhance the differentiated function of osteoblasts (9). Disregulated function of BMPs 
and other TGF-β like proteins resultes in a variety of diseases ranging from skeletal 
abnormalities to metabolic disorders (10).  
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Figure 1.1 Phylogenetic comparisons of mature ligands in the TGF-β superfamily (reviewed by Sebald et al.). Only 
human proteins are included with the exception of BMP-8b and GDF-3 which are from mouse (2). 
 
1.2 TGF-β signaling pathway and receptors 
 
Activity of TGF-β superfamily members is initiated by binding to both type I and type 
II serine/threonine kinases receptors, leading to phosphorylation of the cytoplasmic 
serine/threonine kinase domains (11, 12). In mammals, seven type I receptors and five 
type II receptors have been identified (Fig. 1.2A) (1, 12). The type I receptors have 
similar sizes (50-55 KDa) and 60-90% amino acid sequence identity in their kinase 
domains. Type I receptors are more similar to each other than they are to the known 
type II receptors (approximately 70 KDa) (13，14). Both type I and type II receptors 
are composed of an N-terminal extracellular ligand binding domain, a transmembrane 
region, and a C-terminal serine/threonine kinase domain. 
Type I receptors contain a conserved sequence (SGSGSG) known as the GS domain 
(also called type I box) in their cytoplasmic juxtamembrane region (15, 16). The 
activation of the type I receptor involves the phosphorylation of its GS domain by the 
type II receptor; hence an active receptor signaling complex comprises both types of 
receptors bound to ligands (17, 18). The type I receptors then transduce downstream 
signals by phosphorylating receptor-activated Smad proteins. Based on functional and 
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structural differences, Smads can be classified into three subfamilies: 
receptor-activated Smads (R-Smad), common-partner Smads (Co-Smad), and 
inhibitory Smads (I-Smad) (13). Whereas Smad1, Smad5, and Smad8 are 
phosphorylated by BMP type I receptors (ALK-2, ALK-3, and ALK-6), Smad2 and 
Smad3 are activated by TGF-β and Activin type I receptors (ALK-5 and ALK-4). The 
R-Smad and Co-Smad (Smad4) form a hetero-oligomer which translocates into the 
nucleus and regulates expression of ligand-responsive genes. Inhibitory Smads include 
Smad6 and Smad7, which negatively regulate TGF-β signaling by competing with 
R-Smads for receptors or Co-Smads interaction, and by targeting the receptor for 
degradation (13).  
There are two distinct modes of the ligand-receptor interaction in the TGF-β 
superfamily signaling (11). One is represented by members of BMP subfamily and the 
other exemplified by TGF-βs and Activins. BMP ligands, such as BMP-2 and BMP-4, 
exhibit a high affinity for the extracellular ligand binding domains of type I BMP 
receptors and a low affinity for type II receptors. The preassembled type I 
receptor-ligand complex has a higher binding affinity for the type II receptor (11). In 
contrast to BMPs, TGF-βs and Activins display high affinity for the type II receptors. 
The ligand binds tightly to the type II receptor first, which allows the subsequent 
incorporation of the type I receptor, forming a large ligand-receptor complex 
involving a ligand dimer and four receptor molecules (11). 
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Figure 1.2 A. Sequence similarities of receptor ectodomains in the TGF-β superfamily (reviewed by Sebald et al 
(2).). B. Type I and type II receptors involved in the signaling pathway of TGF-β superfamily members and their 
ligands (reviewed by Balemans W et al (19).).  
 
The interactions of two kinds of receptors with ligands are promiscuous, and this 
means the receptor can bind with different TGF-β superfamily proteins and one ligand 
can bind to different receptor chains (Fig.1.2B). However, accumulated evidence 
shows that there is specificity in these interactions. BMPR-IA preferentially binds to 
BMP-2 over BMP-7 and GDF-5, BMPR-IB binds preferentially to GDF-5 and BMP-7 
over BMP-2 (20, 21). ActR-IB binds the activins and myostatin (22). TGFR-I is 
specific for the TGF-βs and possibly for myostatin. Moreover, Type II receptor chains 
are less discriminatory in binding with ligands. ActR-II, ActR-IIB and BMPR-II have 
been shown to interact with BMP-2, BMP-7 and GDF-5. 
 
1.3 Structure of TGF-β-like proteins and BMPs  
 
Like all members of TGF-β superfamily, BMPs are synthesized as precursor proteins, 
consisting of a signal peptide, pro-domain and mature peptide. BMPs are matured by 
cleavage of a large proprotein by proteases. The mature monomer of TGF-β 
superfamily represents the C-terminal segment of about 100 residues and 6-41 
additional residues at the N-terminus (2). The proprotein has about three times the 
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length of the mature protein. BMP-2 is synthesized as a 453 residues proprotein, 
which becomes glycosylated, proteolytically cleaved and dimerized to yield the 
mature homodimeric protein consisting of 114 C-terminal proprotein residues. Similar 
to other members of TGF-β superfamily, BMP-2 contains a conserved cystine-knot 
which comprises two consensus sequences, C43-X-G-X-C47 and C111-X-C113. The 
cystine bridges between C43/C111 and C47/C113 form a ring-like structure with the 
main chain. A third disulfide bond C14/C79 passes through the ring thus forming the 
knot (2, 23, 24). 
 
According to the structures of TGF-β superfamily members that have been 
characterized, typical features include two separated antiparallel β-sheets, the second 
of which adopts a twisted crossover conformation, and a four-turn α-helix 
approximately perpendicular to the strands (23). The β-sheets can be further divided 
into nine β-strands. The monomer is commonly described as an open left hand with 
the N-terminal end as the thumb, the two β sheets (each two-stranded) as the two 
fingers and the central α-helix as the wrist (Fig. 1.3A). To date, the crystal structure of 
TGF-β2, TGF-β3, GDNF, BMP-7, BMP-2, GDF-5, BMP-6, BMP-9 and solution 
structure of TGF-β1 have been determined (25, 26). There are little differences in 
some structural elements between BMPs and TGF-βs at the basis of their common 
structure (Fig. 1. 3A) (23).  
 
The native BMP-2 is a homodimer and the subunits are covalently linked by a single 
disulfide bond (Cys78 from both subunits). The BMP-2 dimer is antiparallel 
associated (23). In the BMP-2 dimer, the wrist of one monomer fits into the concave 
side of the fingers of the other monomer (Fig. 1.3B). Intersubunits contacts are 
formed by interaction of helix α3 from one monomer with the β-sheets of the other 
monomer. The topology of BMP-2 dimer is highly conserved within the TGF-β 
superfamily, but it is different to other cystine-knot proteins, like PDGF, VEGF and 
NGF. (27, 28). 
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Figure 1.3 Secondary structure elements (A) and crystal structure of BMP-2 (B). A, Helices are indicated as 
cylinders, β-strands as arrows. Secondary structure elements that are part of the TGF-β/BMP basic-scaffold are 
colored blue. Orange helices (α1 and α2) are uniquely found in TGF-βs, while the red helix is unique to BMP-7 
(α4), and the green helix is unique to BMP-2 (β5α) (23). B, Ribbon model presents a view of BMP-2 along the 
2-fold axis and shows the location of the wrist and knuckle epitopes. 
 
BMP-2 has low solubility properties under physiological conditions, similar to other 
BMP members and TGF-βs and GDFs. One explanation is that the surface of BMP-2 
exposes 4 large hydrophobic areas (23).  
 
1.4 Crystal Structure of BMPs with receptor ectodomains 
 
Crystal structure of BMP-2 and BRIA is composed of one BMP dimer and two BRIA 
extracellular domains, which interact with the wrist epitope of the ligand. The contact 
is from both BMP-2 monomers, which is formed by the wrist of one monomer and the 
inner finger region of the concave side of the other monomer (29) (Fig. 1.4A). In the 
BMP-7/ActRII-ec complex, the type II receptor binds to the knuckle epitope formed 
only by the back side of the finger regions of one BMP-7 monomer (21) (Fig. 1.4B). 
The ternary complex of BMP-2/BRIA/ActIIB (ActII) comprises one BMP-2 dimer, 
two BRIA and two ActIIB (ActII) ectodomains. In the crystal structure, the receptor 
ectodomains bind independently and have no direct contacts. The BMPs function as 
rigid scaffolds, which hold the receptor ECDs together for transactivition (30, 31) (Fig. 
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1.4C and 4D). 
 
 
 
Figure 1.4 Crystal structures of BMPs with receptor ectodomains. A, BMP-2 and the receptor BMPR-IA 
ectodomain. (30). B, BMP-7 and the receptor ActR-II ectodomain (22). C, Crystal structure of BMP-2 bound to 
one receptor ectodomain of BMPR-IA and ActR-IIB (31). D,Ternary complex of BMP-2/BMPR-IA/ActR-II (32). 
 
In the complex of BMP-2 and BRIA, the total buried solvent accessible surface area 
upon binding of one receptor molecule is 2.260Å2. Of the 1130Å2 in the BMP-2 dimer 
that are buried, 68% is from BMP-2A and 32% is from BMP-2B. Altogether, 27 
residues from BRIA and 26 residues from BMP-2 are involved in ligand-receptor 
interactions, of which 15 are from BMP-2A and 11 are from BMP-2B (29). The 
interaction of BMP-7 and ActRII is hydrophobic with a buried surface area of 676 Å2 
per subunit. It is mainly composed of side chain interactions providing a structural 
scaffold on which the binding specificity can be encoded by amino acid identities 
(21).  
 
BMPs and other TGF-β like proteins have two kinds of functional epitopes for 
receptor binding. The crystal structure of BMP-2 and BRIAec complex shows that 
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elements of both BMP-2 monomers build the “wrist” epitope and binds type I receptor 
ectodomains (ECD) (Fig. 1.5A). The pre-α-helix loop and the α-helix from one 
monomer (the wrist of the hand–like monomer) together with the concave side of the 
fingers of the second monomer create this epitope (32, 33). Central to the hydrophobic 
interface of BMP-2/BMPR-IA is Phe85 of BRIAec, which sticks out of the receptor 
helix α1 and fits into a hydrophobic pocket on the ligand where it is surrounded by 8 
hydrophobic residues from both BMP-2 monomers. The residue Phe85 is conserved 
in all type I receptors, raising the possibility that this “knob-into-hole” motif possibly 
determines the specificities of type I receptor/ligand interactions. The “knuckle” 
epitope is also hydrophobic. It is constituted by one monomer only and binds type II 
receptor ectodomains (Fig. 1.5B) (21). Both epitopes are promiscuous and each of 
them can interact with several different receptor chains.  
 
 
 
Figure 1.5 A Structural epitopes of BMP-2/BMP-7 for binding of type I and type II receptors. A, Residues buried 
in the surface in the wrist epitope of BMP-2 in complex with BMP-IA ectodomain (2, 33). B, Residues buried in 
the surface in the knuckle epitope of BMP-7 in complex with ActR-II ectodomain (21).  
 
A 
B 
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1.5 Binding affinity and specificity of BMP/receptor interactions 
 
The residues of BMP-2 that determine binding affinity and specificity for both type I 
and type II receptor binding have been identified by submitting a large array of 
BMP-2 mutants by Biacore interaction analysis with the receptor ectodomains (33, 
34). 
 
In the early study, mutational analysis identified only side chains of minor importance 
(33, 35, 36 and 37). The elusive binding determinants for BMP-2/BMPR-IA 
interaction were finally identified by scuritising the ten hydrogen bonds predicted to 
occur at the interface (34). A BMP-2 L51P mutant which has lost one of the central 
hydrogen bonds due to the introduced proline showed about 5000-fold lower affinity 
to BRIA and BRIB than the wild type, but still has the similar affinity to type II 
receptors. Thus L51P is known as “receptor-dead” mutant. The amide and carbonyl of 
Leu51 of BMP-2 form two hydrogen bonds with Q86 of BRIA. Interestingly, the 
mutant Q86A has a 100-fold reduced affinity for BMP-2 compared to that of the wild 
type receptor (34). Residue Leu51 is invariant in members of the BMP-2-BMP-4, 
BMP-5-BMP-6-BMP-7, and GDF-5-GDF-6-GDF-7 protein subfamilies, all of which 
interact functionally with the receptors BRIA and BRIB. Gln 86 of BRIA is invariant 
in the BRIB receptor but not in other type I chains. This suggests that the hydrogen 
bonds between these residues are important for the binding of all the BMPs and GDFs 
to the BRIA and BRIB receptors (34). 
 
The binding of the “receptor-dead” BMP-2 mutant L51P to modulator proteins such 
as Noggin, chordin and gremlin is unchanged (34) indicating that binding 
determinants of BMPs for type I receptor and Noggin are different. This allows the 
L51P mutant to neutralize Noggin inhibition on BMP induction of alkaline 
phosphatase (ALP) in C2C12 cells. Thus, L51P mutant could be used as a 
receptor-inactive inhibitor of Noggin.  
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Mutational analysis of BMP-2 has identified A34, H39, S88, L90, and L100 in the 
knuckle epitope as minor binding determinants for BMPR-II and ActR-II (33). 
However, no binding hot-spot was found in the knuckle epitope. The central hydrogen 
bond with type II receptors ActR-II and ActR-IIB can be disrupted in the BMP-2 
S88A mutant with minor effects on binding affinity (31). This central H-bond is 
highly conserved and exists also in the ActA-ActR-IIB contact, which in contrast 
determines high-affinity binding (31). Remarkably, some BMP-2 mutants at the 
border of the knuckle epitope exhibit strongly increased affinity specifically for 
ActR-IIB, e.g. L100K and L100K/N102D (31) or for BMPR-II (E109R) (38). In 
contrast, other mutations, e.g., BMP-2 A34D, disrupt binding of type II receptors 
resulting in antagonistic variants (30). 
 
1.6 Modulator proteins of BMP signaling 
 
The BMP signaling is subject to stringent regulation at multiple levels. These include 
the intracellular modulation, membrane receptor modulation and extracellular 
modulation (19). Intracellularly, Inhibitory Smads (I-Smads), i.e., Smad6 and Smad7, 
as intracellular regulators, can antagonize the TGF-β signaling pathway either by 
interacting with phosphorylated type I receptors and thereby preventing the activation 
of R-Smads, or through competition with Co-Smads for the formation of the 
R-Smad/Co-Smad complexes (39). The inhibitory regulation of I-Smads is likely 
regulated by negative feedback signal from TGF-β superfamily members (40). At the 
cell surface, pseudoreceptors like Bambi (Bmp and activin membrane-bound inhibitor) 
can attenuate BMP signaling. The Bambi gene encodes a transmembrane protein 
highly similar in amino acid sequence to type I serine/threonine kinase receptors in 
the extracellular domain. However, the Bambi intracellular domain is short and lacks 
a serine/threonine-kinase domain that is essential for transducing TGF-β signaling (41, 
42). Biochemical assays showed that Bambi interacts directly with serine/threonine 
kinase receptors and antagonizes BMP signaling (41). Finally, a large number of 
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modulator proteins exist in the extracellular space, which inhibit and/or enhance the 
receptor-mediated activity of BMPs by directly binding to BMPs. These proteins 
include Noggin, Follistatin, members of the DAN family, Chordin and others (Fig. 1. 
6).  
 
 
 
Figure 1.6 BMP signal pathway (modified from Balemans et al.).  
 
1.6.1 Noggin and Follistatin   
 
One of the most investigated BMP extracellular regulators is Noggin. Noggin is 
expressed during early stages of gastrulation in the Spemann organizer, where it 
promotes the development of dorsal tissues, such as muscle and nervous tissue (43). 
Only one single Noggin homolog was identified in the vertebrates, in the zebrafish 
embryo, where three Noggin isoforms have been isolated, namely Noggin1, Noggin2, 
and Noggin3. Although the zebrafish Noggin isoforms show different expression 
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patterns, all have dorsalizing activities by antagonizing BMP signaling (44). 
 
Noggin is a secreted and homodimeric protein whose primary structure consists of an 
acidic aminoterminal region and a cytokine-rich carboxyterminal region containing a 
cystine knot (45). A central, highly basic heparin-binding segment retains Noggin at 
the cell surface. Noggin is known to bind BMPs/GDF5 with very high affinity (46, 
47), and the binding is almost irreversible due to a slow dissociation rate constant. 
The crystal structure of Noggin and BMP-7 complex has revealed for the first time 
how one of the regulators binds to the ligand and prevents it from contacting 
membrane receptors. It shows that Noggin occupies both two knuckle and two wrist 
epitopes of the receptor binding sites, and inhibits BMP signaling in this strong 
manner (Fig. 1.7) (45). Each monomer of Noggin contains an extended N-terminal 
clip segment of about 20 residues, which wraps around a BMP-7 monomer, directly 
occupying part of the wrist epitope. A proline residue in this segment, Pro35, fills the 
BMP-7 hydrophobic pocket that normally accommodates Phe85 in the type I receptor. 
Interestingly, Noggin contains a cysteine knot topology that is similar to that of BMPs, 
which suggests that they evolved from a common ancestral gene (45).  
 
The BMP-7 binding affinity of the site-specific variants of Noggin is correlated with 
alterations in bone formation and apoptosis in chick limb development, showing that 
Noggin functions by sequestering its ligand in an inactive complex (45). Furthermore, 
familiar Symphalangism (48) results from the heterozygous mutation P35S in the clip 
region, confirming the importance of the N terminus of Noggin in vivo. 
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Figure 1.7 Crystal structure of Noggin-BMP-7 complex provides a paradigm for the mechanism of BMP inhibition 
by a secreted antagonist. 
 
The three-dimensional structure of Noggin-BMP-7 complex provides a paradigm for 
the mechanism of BMP inhibition by a secreted antagonist. However, for the 
interaction of BMPs and Noggin the functional epitope(s), i.e. the residues 
determining binding affinity and specificity, are still poorly understood.  
 
 
 
Figure 1.8 Overview of the Follistatin:ActivinA Complex. A, Ribbon diagram of the follistatin:activin complex 
(topview). B, Overlay of the individual follistatin domains1-3 using their Kazal-like domains (49).  
 
The crystal structure of Follistatin, another BMPs signal regulator, was also 
determined (49, 50). In Follistatin-activin complex, two follistatin monomers 
surround the dimeric ligand and bury the binding sites for type I and type II receptors 
(Fig. 1.8) (49, 50). Mutational analysis revealed that only residues at the type II 
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receptor-binding surface of activin are critical for high-affinity follistatin binding, and 
the interaction surface of activin for type II receptors and follistatin are overlapping 
but not identical (51). Furthermore, a dissection of the follistatin domain structure 
revealed that the unique N-terminal Fs0 domain, which as a pseudo type I receptor 
contacts the wrist epitope of activin, appears to be dispensable for activin interaction 
(50). 
 
1.6.2 Von Willebrand Factor type C domain (VWC) containing proteins  
  
Among the BMP signaling regulatory members, there is a large number of 
extracellular regulator proteins that contain von Willebrand factor type C domain 
(VWC domain, also called cystiene-rich domain, CR domain). The VWC domains 
have ten cysteins with a conserved spacing pattern: typically with a conserved 
CXXCXC motif in the middle and a CCXXC motif in the C-terminus. In this 
nomenclature ‘X’ can be any amino acid. In addition, a glycine and a tryptophan 
residue located between the first two cysteins are highly conserved (52, 53). The 
VWC domains exist in about 500 extracellular proteins from Drosophila to human (83 
proteins in Homo sapiens and 85 proteins in Mus musculus) (54). Many 
VWC-containing proteins act as extracellular modulators in the BMP/TGF-β 
signaling pathway. They act as an antagonist or agonist of TGF-β signal by binding to 
a range of TGF-β superfamily members through their VWC domains (55, 56, 57, 58). 
For instances, one VWC domain-containing protein CTGF (connective tissue growth 
factor) inhibits BMP signaling, but promotes TGF-β activity (55), while the 
multi-VWC domain-containing protein Kielin could enhance BMP signaling while 
suppress TGF-β activation (56, 57, 58).  
 
Numerous extracellular proteins that contain large numbers of VWC domains such as 
CRIM-1, Kielin/kielin chordin-like protein (KCP), Crossveinless-2 (CV2) and 
Neuralin/ CHL have been identified (Fig. 1.9). (59, 60, 61, 62, 63). To date, there are 
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~ 500 proteins containing more than one VWC domains, and some of which have 
physical interactions with BMPs.  
 
 
 
Figure 1.9 Domain compositions of VWC-containing proteins of zebrafish Corssveinless 2 (zCV2), mouse 
Chordin (mChordin) and mouse Kielin/Kielin Chordin like protein (KCP). The black boxes indicate signal peptide; 
red boxes indicate Von Willebrand factor type C domain (VWC); green box indicates trypsin inhibitor-like    
cysteine-rich domain (TIL); yellow boxes indicate Von Willebrand factor type D domain (VWFD).  
 
1.6.2.1 Chordin 
Among the increasing number of VWC-containing proteins, one representative is the 
widely studied Chordin/Sog (the Drosophila homology of Chordin). Chordin is a 
protein of 120 kDa with 4 VWC domains secreted by Spemann’s organizer (64). It 
binds to BMPs in the extracellular space, preventing the interaction of BMPs with 
their receptors (65). Chordin plays important roles in the dorsalventral patterning 
determination of the animal embryo (66). The BMP antagonist activity of chordin has 
been pinpointed to the VWC domains (52, 54). 
 
Chordin mainly acts as an antagonist of BMP signaling by binding to BMPs via its 
VWC domains, but this could be regulated by Tollid or Tsg. The regulation of 
Sog/Chordin activity in Drosophila, zebrafish, Xenopus and mice has been 
extensively studied, in particularly its inactivation after cleavage by the 
metalloprotease Xolloid or Tolloid (65, 67, 68, 69). It has been shown that the 
cleavage of Chordin by Xolloid/Tolloid releases BMP from an inhibitory Sog/Dpp or 
Chordin/BMP complex. This cleavage occurs at two sites, resulting in proteolytic 
fragments containing the individual VWC1, VWC4, and a longer product containing 
both VWC2 and VWC3 (53). The antagonistic activity of Chordin is stringent in the 
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presence of Tsg, through the formation of a Chordin:BMP:Tsg ternary complex. After 
cleavage of Chordin by Xolloid, BMP is released from chordin, but remains bound to 
Tsg (BMP:Tsg binary complex). Following this, Tsg dislodges BMP from the 
Chordin VWC domains, allowing the efficient transfer of BMP to the receptor and 
signaling (Fig. 1. 10) (70, 71, 72, 73). 
 
Figure 1.10 Model for a biochemical pathway that regulates BMP signaling in the extracellular space. Tsg-BMP 
complexes can be bound by full-length Chordin to form a ternary complex that is a potent BMP antagonist. 
Xolloid cleaves Chordin releasing Tsg-BMP binary complexes and Chordin fragments. In the presence of 
full-length Chordin, the binary complex will re-bind to Chordin, re-forming the ternary complex. Full-length 
Chordin is then cleaved by Xolloid. Tsg is able to dislodge BMP from Chordin and to destabilize the Chordin 
proteolytic products, displacing the equilibrium. This model explains why Tsg has the dual ability to increase BMP 
antagonism by full-length Chordin and to promote BMP signaling after Xolloid cleavage (from Larrain J et al., 
2001).  
Shimmi et al (2005) proposed a model for Patterning Dorsal Tissues in the 
Drosophila embryo, where Sog and Tsg play important roles (Fig. 1.11). Homodimers 
and heterodimers of Dpp and Scw are produced throughout the dorsal domain. Sog is 
expressed and secreted in the ventral lateral region and diffuses toward the dorsal side. 
Dpp and Scw homodimers do not bind to Sog and Tsg with high affinity. As a result, 
they are free to bind with receptors, but they produce only low-level signals that can 
activate targets such as pnr. In contrast, Dpp/Scw heterodimers bind with high affinity 
to Sog and Tsg. Net flux of the complex toward the dorsal midline leads to an increase 
in the heterodimer concentration at the midline. Tld processes Sog at the midline to 
release the ligand, which then binds to a receptor complex containing both Sax and 
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Tkv. This complex produces a synergistic high signal that activates high-level 
response genes such as race and leads to specification of the amnioserosa (74).  
 
Figure 1.11 Schematic model for Patterning Dorsal Tissues in the Drosophila Embryo (from Shimmi et al., 2005). 
The binding affinity of chordin VWC domains to BMP-2/-7 and GDF-5 was analyzed 
(54). VWC1 and VWC3 of chordin were found to bind to BMP-2. However, BMP-7 
bound to immobilized VWC1 with an affinity about 5 times higher than that of 
BMP-2 to VWC1. It bound to VWC3 very weakly but bound to VWC4 with 100-fold 
higher affinity (23 nM) than that of BMP-2 to VWC4. GDF-5 bound to chordin with a 
very low affinity (binding affinities for chordin VWC1 and VWC3 are only 180 nM 
and 1 µM). No binding was found between chordin VWC2 and BMP-2/-7 or GDF-5. 
These results suggest that BMP-2 preferentially binds to VWC1 and VWC3 of 
chordin; BMP-7 binds to VWC1 and VWC4, and GDF-5 binds weakly to chordin and 
its VWC domains (54). 
 
BMP regulator proteins have different specificities and affinities for BMPs (54). 
Therefore, different binding epitopes for the modulators may exist in the BMPs. To 
better understand the regulatory mechanisms of these proteins, it is necessary to know 
how these binding epitopes are constructed, how they overlap with the 
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receptor-binding wrist and knuckle epitopes, and whether inhibitors could be 
generated that are specific for each type. Chordin is one of the investigated proteins 
whose binding epitopes for BMPS are well examined among the BMP regulator 
proteins.  
 
Binding affinity analysis by biacore showed that many of the knuckle epitope BMP 
mutants such as A34D, S88P, L90A, V98P, L100P, L100K and L100K/N102D, bound 
to Chordin with reduced affinity, suggesting that the binding epitopes of BMP-2 for 
chordin overlap with the knuckle epitope (54). M106A, a BMP wrist epitope mutant, 
also exhibited 11-fold lower affinity for chordin. M106A has a 100-fold lower b 
affinity for chordin VWC1 than that for the wild type, suggesting that M106 is a hot 
spot for binding with VWC1. M106A bound to chordin-VWC1 with ten-fold lower 
affinity than to chordin-VWC3, although the other determinants of the BMP-2 
knuckle epitope for chordin-VWC1 and -VWC3 are very similar (54). In general, 
mutational analysis of BMP-2 predicted an overlapping of the binding epitope for 
Chordin mainly with the knuckle epitope for type II receptors. However, the reduced 
binding affinities of chordin to the M106A variant suggest that its binding epitope is 
also partially overlapping with the wrist epitope.   
 
Co-precipitation experiments showed that chordin competes with type I receptors 
(BMPR-IA or BMPR-IB) for BMP-4 binding (28, 45). In a Biacore interaction 
analysis, 100 nM full length Chordin was found to completely inhibit the binding of 
50 nM BMP-2 to both immobilized BMPR-IA and ActR-IIB (54). Chordin-VWC1 
was able to block the binding of BMP-2 to BMPR-IA and ActR-IIB at high 
concentration. However, chordin-VWC3 that mainly binds to the knuckle epitope of 
BMP-2, displays no inhibition on BMP-2/BMPR-IA interaction even with 4 µM, and 
it could inhibit BMP-2/ActR-IIB binding by only 50% at this concentration. These 
results indicate that the single VWC domains are able to inhibit the binding of BMP-2 
to type I and/or type II receptor(s) in vitro and their inhibitory efficiency correlates 
with the binding affinities for BMP-2. 
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Cell culture experiments showed that Chordin inhibited alkaline phosphatase (ALP) 
activity induced by 10 nM BMP-4 with an IC50 value of about 15 nM (75). However, 
neither VWC1 nor VWC3 of chordin showed inhibitory activity up to a concentration 
of 1 µM. Interestingly, the chordin-VWC1 domain, at a concentration of 1 µM,  
inhibited BMP-2/BMPR-IA and BMP-2/ActR-IIB interactions in an in vitro 
competition experiment, but could not inhibit BMP-2-induced ALP activity at the 
same concentration (54). Thus, for the single VWC domain the in vitro and in vivo 
activities are not strictly correlated. One explanation is the binding affinity of Chordin 
VWC domains to BMPs is not high enough, therefore no inhibitory activity could be 
induced in the cell assay.  
 
1.6.2.2 Crossveinless 2   
Crossveinless 2, another member of Chordin-like protein family, is an evolutionary 
conserved extracellular regulator of the Dpp/BMP signaling pathway. CV2 was first 
detected in Drosophila where it is required for signaling of BMP homologs Dpp and 
Gpp during the formation of cross-veins in the developing wing (76, 77). 
Accumulating evidence has show that CV2, as a VWC domain-containing protein, 
plays important roles in embryogenesis, dorsalventral patterning and organogenesis 
through regulation of BMP signaling (78, 79, 80, 81, 82). 
 
The expression of zebrafish CV2 is correlated with that of BMP, and it is under the 
positive control of BMP signaling (78). Mouse CV2 is expressed dynamically during 
development, particularly in areas of high BMP activity such as the posterior 
primitive streak, ventral tail bud and prevertebral cartilages (79, 83). CV2 +/- 
knocked-in mice analysis showed that CV2 is expressed in a number of developing 
skeletal structures and internal organs such as vertebral body and arch, ribs, skull and 
long bones, lung and kidney during the organogenetic stages (79). CV2 has been 
identified as BMP-binding endothelial cell precursor-derived regulator (BMPER) 
which is expressed in flk-1 positive endothelial precursor cells (81). In adult animals 
CV2 is strongly expressed in the lung, but less in brain and heart. In addition, primary 
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chondrocytes but not osteoblasts express high levels of CV2 (82).  
 
Like Chordin, CV2 is also a secreted protein and can physically interact with BMPs. 
CV2 binds BMP-2, BMP-4 and BMP-6/-7 with high affinity but interacts only weakly 
with GDF-5 (78, 81). The affinity of CV2 binding to BMP members are similar to 
BMP-2 binding to type I receptor BRIA (34). Both CV2 regulated enhancement and 
inhibition of BMP signaling have been reported. Loss-of-function analysis of CV2 by 
morpholino knockdowns show that CV2 acts as a BMP signal-promoting factor 
during early dorsoventral patterning of zebrafish embryos (78). While gastrulation is 
normal in CV2 knockout mice, a number of later defects are observed in the 
development of skeleton, eye and kidney, consistent with the phenotypes that can also 
be genetically enhanced by the loss of BMP signaling (79). In invertebrates, CV2 was 
reportedly only required for enhancing BMP signaling during wing vein development 
(80). Gain of function results are not as clear as that of loss of function, and both pro- 
and anti- BMP signaling have been described. Microinjection of CV2 mRNA into the 
Xenopus embryo results in the formation of a secondary axis similar to that induced 
by Noggin and Chordin (80, 81). In cell culture experiments, hCV2 was found to 
inhibit BMP-dependent Osteoblast and Chondrocyte differentiation (82). Mouse CV2 
can reduce activation of the BMP-dependent luciferase reporter (81). These 
phenotypes could not be only explained by CV2 overexpression, because CV2 could 
also enhance BMP-4 mediated phosphoralation of Smad1 in cell culture (84); 
Coinjection of CV2 and BMP-4 mRNA into Xenopus animal pole blastomeres 
synergistically induce the ectopic expression of xbra., which is significantly higher 
than injection of the same amount of BMP-4 mRNA alone (85).  
A processing site (G352DPH) is located between the fifth VWC domain and the 
VWFD domain of full-length zebrafish CV2 (Fig. 1.10) (78, 81), which is also 
confirmed in Drosophila CV2. After the cleavage the N- and C-terminal parts are 
detected to associate by a disulfide bond, which is likely formed by C383 and C520 in 
Drosophila CV2 (78). The cleavage converts CV2 from a dorsalizing to a ventralizing 
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factor in zebrafish embryos, since injection of CV2-N construct containing VWC 
domains 1-5 into the zebrafish embryos led to a ventralized phenotype, and the 
cleavage-resistant mutant (CV2-CM) construct in which the cleavage site was 
destroyed caused a strong dorsalization. Wild type CV2 can both dorsalize and 
ventralize, and the effect was similar with the coinjection of CV2-N and CV2-CM 
(78). Both cleaved and uncleaved CV2 strongly bind BMPs, and the binding was via 
its N-terminal VWC domain (78). In Drosophila the GDPH cleavage of CV2 is not 
caused by the proposed low pH that can trigger the cleavage occurrence via an 
autocatalytic process in other secreted proteins (86). Until now, the existence types of 
CV2 in vivo are unclear, but it is possible that the cleavage exists during the 
embryogenesis, and the proteolytic cleavage is an important regulatory factor for CV2 
modulating BMPs signaling. However, it was found that drosophila CV2 promoting 
BMP signaling does not require the cleavage of CV2 (Serpe et al., unpublished). 
It is likely that binding to the extracellular matrix for uncleaved CV2 is another factor 
for its regulation of BMPs signaling. Studies have shown that the uncleaved CV2-CM 
bound to extracellular matrix (ECM), but the cleaved one did not. CV2 contains 67 
basic amino basic amino acids as potential binding site for HSPGs. Deletion of 4 
amino acids that conforms to a consensus heparin binding sites from mutant CV2-CM 
reduced the affinity of heparin binding. Injection of this mutant led to a strongly 
reduced dorsalizing activity compared with CV2-CM (78). The association of BMP 
modulator proteins Noggin and Chordin with ECM via the HSPG binding have shown 
an important role in the regulation of BMP signaling (86, 87, 88, 89). Thus, more 
information is rquired to understand the effect of heparin binding of CV2. 
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MLCLSPPVTYNLLFWFLILQTPQSTAPLITGTEASCENEGEVLHIPNITDNPCISCVCLNQ
KAECKQEKCAPLAEDCALVVKQTGACCEKCKGCLLKGTSYNSSHHWISPVKPCVTYSC
QEGVITEAEMRCVIHCKNPKIHPKKCCPTCPGCIFEGNLYKEDEEFHPEGNPCIKCVCT
GGQSMCHKLVCPVLSCPSHLTHTPPGQCCPRCRGQRRVFDLSPGSCLFHSEVYENGSSIS
YDNCTTCTCVDSTVLCRKRCSPPGSCHGTACCEACQSHLKMEDVKYCRVKSKIYRDGD
RWSSVNCSLCTCVKGNIQCQPKICVPITSCPSNKILNRTGCCPVCTDKPGVCTVFGDPHY
NTFDGRTFNFQGTCKYVLTKDCSPAASFTVLVKNDARRTRSFSWTKSVELHTSGLSISLH
QHLTVRQNGTRIALPFHSTGVHIDLDGYLLKLTTIAGLEITWDGDSLVEVVAAPHLKGQ
LCGLCGNYNGQRRDDSLGGDGQFKFDVDELAESWRVEDNELCEVQNRRPTSFLCAGT
VKVKLRAHRTCQKLKSWEFQKCHSAVDFTSFYKSCVTDMCECPVHKNCFCESFIAYSR
AREREGIHVHWRPELTCMSTHCKHGAVYDTCGPGCTKSCHNWNEIGPCQRPCIAGCHC
PASLVMFQGHCIKPTSCPGR 
 
Figure 1.12 Amino acid sequence of zebrafish CV2. VWC1 domain is shown in red, VWC2 domain is shown in 
green, VWC3 is shwon in blue, VWC4 is shown in purple and VWC5 is shown in gold. All VWC domains are 
underlined. The c-terminal including VWFD domain and TIL domain are marked in brown colour. The GDPH 
processing site is underlined. 
Other BMP extracellular regulators also contribute to the CV2 regulating mechanism. 
Another chordin like protein KCP, which containing 17 VWC domains in the mouse 
protein, can enhance BMPs signaling but reduce TGF-β/Activin signaling. It has 
overlapping function with CV2 in regards to BMP signaling. KCP knockout mice 
show no gross structural defects, but are more susceptible to renal interstitial fibrosis, 
a condition which can be suppressed by enhanced BMP signaling (85). The kidney 
defects observed in CV2-/- mutants are enhanced by loss of KCP (79). 
 
It is possible that both pro- and anti- BMPs signaling functions of CV2 exist together 
in vivo, and there is a balance between the two functions. The interaction of CV2 with 
other unknown factors, the heparin binding, the spatial and temporal expression of 
CV2 should always be considered comprehensively in explaining the mechanism of 
CV2 regulating BMP signaling. 
 
Crossveinless 2 contains 5 closely spaced VWC domains in the N-terminal segment, a 
von Willebrand Factor D (VWFD) domain and a trypsin inhibitor-like cysteine-rich 
(TIL) domain in the C-terminal region (Fig. 1.9). The linkers between 5 VWC 
Introduction 
 - 23 - 
domains are very short, varying from 2 to 13 amino acids. Every domain contains 8 or 
10 cysteines and the conserved CXXCXC/CCXXC consensus. Each VWC domain of 
CV2 contains about 50-60 amino acids from the first cysteine to the last cysteine (Fig. 
1.12). It has been demonstrated that the BMP binding of CV2 is strictly confined to its 
VWC1-5 domains (78), therefore, the VWC domain has been taken as the main target 
of this thesis. 
 
To date, only one structure of the VWC domain has been determined. The solution 
structure of Collagen IIA (ColIIA) VWC domain exhibits a two subdomain 
architecture tethered by a flexible linkage (PDB code: 1u5m). The N-terminal 
subdomain contains a double-stranded anti-parallel ß-sheets and a triple stranded 
anti-parallel ß-sheet. The C-terminal subdomain adopts a more irregular structure (Fig. 
1.13). In this structure, disulfide bonds were assigned as C1-C4, C2-C8, C3-C5, 
C6-C9 and C7-C10. This study established for the first time the two-domain 
architecture of the VWC domain and the similarity of the subdomain 1 of VWC with 
fibronectin type I (FNI) module (90). 
 
Figure 1.13 Solution Structure of Collagen IIA VWC domain. The N-terminal subdomain is colored blue and 
C-terminal domain is colored yellow. 5 β-strands and 5 disulfide bonds are marked (modified from O’Leary et al., 
2004).  
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However, the VWC protein used for the NMR structure determination does not 
exhibit the BMP-binding affinity originally claimed for the procollagen VWC domain 
(90, 52). Thus, it remains uncertain if the NMR structure of Collagen IIA VWC 
domain represents the functional protein, and it is still unknown if other VWC 
domains share the similar structure. The binding of CV2 to BMP-2/-7 and GDF-5 
occurs via its N-terminal segment containing VWC1-5 (78), although which specific 
domain(s) are involved is not known.  
 
Hitherto, no three dimensional structure of the complex of BMPs with VWC domains 
is available. The aim of this thesis was to solve the crystal structure of the complex of 
BMP-2 and VWC domains, define their binding affinity and specificity, and test the 
biological relevance of the VWC/BMP interaction, in order to provide a structural 
basis for the interaction of BMP and VWC domains. 
 
In this thesis, we first present the crystal structure of the BMP-2 and CV2-VWC1 
binary complex, and then describe how the binding epitopes of BMP-2 and 
CV2-VWC1 are constructed, and how they overlap with the receptor-binding wrist 
and knuckle epitopes.  
 
The structure determined for BMP-2 bound to the VWC1 domain of CV2 provides 
new and interesting data, which in the future will augment an understanding of the 
cooperation of BMP-2 and CV2 during animal development. The structural data 
together with mutational analysis demonstrates a new binding mode for a BMP 
modulator protein differing from the interaction of BMP-7 and Noggin (44) or Activin 
and Follistatin (49, 50). These results provide the first paradigm of VWC structure 
and BMP binding and are likely relevant for the 201 VWC domains present in about 
70 other human proteins. 
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2. Material and methods 
2.1 Bacterial strains 
Table 2.1: Bacteria stains and their features. 
 
2.2 Vectors 
PET 32a: T7 Promoter; lacI Sequence; Thioredoxin A (N-terminal);  
6 x Histidine-tag 
Modification: Delete base pairs from 223 to 297 from the original 
vector (92).  
 
pACGP67B : Polyhedrin promoter; gp67 secretion signal   
Modification (By Dr. Joachim Nickel): Add 6 x Histidine-tag and 
thrombin cleavage sites. 
 
2.3 Oligoes for molecular cloning 
Primers of the CV2-VWC domains 
Pet-S:       CCCGCGAAATTAATACGACTC  
VWC1Ws:     CTGGTGCCACGCGGTTCTTGGTTAATCACCGGTACAGAG 
VWC1Wa.     CTCTGTACCGGTGATTAACCAAGAACCGCGTGGCACCAG 
VWC1A:     CGCGCTCAGCCTATTAACCTTTGCATTTTTCACA 
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VWC2S:     ATACCATGGCCAAAGGTTGTCTTCTGAAA 
VWC2A:     CGCGCTCAGCCTATTACCCTGGACATGTAGGGCA 
VWC3S:      ATACCATGGCCCCAGGGTGCATTTTTGAG 
VWC3A:     CGCGCTCAGCCTATTAGCTGCCTGGCGATAAGTC 
VWC4S:     ATACCATGGCCCGGGGTCAGACCAGGGTG 
VWC4A:     CGCGCTCAGCCTATTATTTCACGTCTTCCATCT 
VWC5S:     ATACCATGGCCCAGTCTCACCTCAAGATG 
VWC5A:     CGCGCTCAGCCTATTACACGCCTGGCTTGTCAG 
 
Primers of the CV2-VWC1 mutants  
VWC1-Clip1Ns: CTGTGCCACGCGGTTCTTGTGAAAACGAGGGAGAA 
VWC1-Clip1Na: TTCTCCCTCGTTTTCACAAGAACCGCGTGGCACCAG 
L1A1:    TGTACCGGTGATTGCCCAAGAACCGCG  
L1A2:    GTTTTCACAGCTAGCCTCTGTACCGGTGATTGCCCA  
L1R1:     TGTACCGGTGATTCGCCAAGAACCGCG  
L1R2:    GTTTTCACAGCTAGCCTCTGTACCGGTGATTCGCCA  
I2A1:    CTCTGTACCGGTGGCTAACCAAGAACC 
I2A2:    CTCGTTTTCACAGCTAGCCTCTGTACCGGTGGCTAA  
I2R1:    CTCTGTACCGGTGCGTAACCAAGAACC 
I2R2:    CTCGTTTTCACAGCTAGCCTCTGTACCGGTGCGTAA  
I18As:    AAGTGTTACACGCGCCCAACATCACA 
I18Aa:    TGTGATGTTGGGCGCGTGTAACACTT 
I18Rs:    AAGTGTTACACCGCCCCAACATCACA 
I18Ra:    TGTGATGTTGGGGCGGTGTAACACTT 
I18Ks:    AAGTGTTACACAAGCCCAACATCACA 
I18Ka:    TGTGATGTTGGGCTTGTGTAACACTT 
I18Es:    AAGTGTTACACGAGCCCAACATCACA 
I18Ea:    TGTGATGTTGGGCTCGTGTAACACTT 
I21As:    ACATCCCCAACGCGACAGACAACCCC 
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I21Aa:    GGGGTTGTCTGTGGCGTTGGGGATGT 
I21Rs:    ACATCCCCAACCGCACAGACAACCCC 
I21Ra:    GGGGTTGTCTGTGCGGTTGGGGATGT 
I27As:    ACAACCCCTGCGCGTCCTGCGTCTGT 
I27Aa:    ACAGACGCAGGACGCGCAGGGGTTGT 
I27Rs:    ACAACCCCTGCCGCTCCTGCGTCTGT 
I27Ra:    ACAGACGCAGGAGCGGCAGGGGTTGT 
A36Rs:    TGAATCAGAAACGCGAGTGTAAGCAG 
A36Ra:    CTGCTTACACTCGCGTTTCTGATTCA 
 
Primers of the CV2-VWC1 mutants for selenomethionine labeling 
S28Ms:    ACCCCTGCATCATGTGCGTCTGTCTG 
S28Ma:    CAGACAGACGCACATGATGCAGGGGT 
N33Ms:    GCGTCTGTCTGATGCAGAAAGCGGAG 
N33Ma:    CTCCGCTTTCTGCATCAGACAGACGC 
K39Ms:    AAGCGGAGTGTATGCAGGAGAAGTGT 
K39Ma:    ACACTTCTCCTGCATACACTCCGCTT 
E41Ms:    AGTGTAAGCAGATGAAGTGTGCACCG 
E41Ma:    CGGTGCACACTTCATCTGCTTACACT 
 
2.4 Solutions   
1. Luria-Bertani Medium (LB medium): 10 g Tryptone, 5 g Yeast extract, 10 g 
NaCl in 1 L dH2O, pH 7.2. 
2. Luria-Bertani-Agar: LB-medium containing 15 g Agar/L. 
Other solutions are listed according to relevant experiments protocols. 
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2.5 Proteins 
 
BMP-2: Produced by Christian Soeder and Prof. Walter Sebald in the Department of 
Physiological Chemistry II.  
Selenomethionine labelled wide type BMP-2 and BMP-2 (Y41M,Y91M): Prepared 
by Dionys Weber, Christian Soeder and Prof. Walter Sebald. 
CV2 and CV2-N: Prepared by Dr. Jinli Zhang, Nicole Hopf and Prof. Walter Sebald. 
GDF-5: Prepared by Dr. Joachim Nickel and Prof. Walter Sebald. 
 
2.6 Molecular biology methods 
 
Standard methods for DNA isolation and manipulation were performed as described 
in Qiagen manual. Phenol/chloroform extraction and ethanol precipitation were used 
for purification and concentration of DNA. Quantification of DNA was carried out by 
using a Bio UV-Visible spectrophotometer at 260 nm as well as by comparing the 
fluorescent intensity with DNA markers on agarose gels. 
 
2.6.1 Agarose gel electrophoresis of DNA 
 
1.0% - 2.0% (w/v) agarose gels were used to separate DNA fragments. The buffer 
system was 1 × TAE buffer. The gels were supplemented with the ethidium bromide, 
detected under the UV light and photographed. Lambda DNA /PstI 24 were used as 
standard markers. DNA fragments were excised and isolated from agarose gels using 
gel extraction kit (Promega) according to mannul. 
 
2.6.2 Isolation of plasmids from E. coli    
 
Buffer 1: 25 mM Tris-Cl pH 8.0, 50 mM Glucose, 10 mM EDTA 
Buffer 2: 0.2 M NaOH, 1% (w/v) SDS 
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Buffer 3: 3.0 M Kac pH 4.8 
TE buffer: 10 mM Tris-Cl, pH 7.5. 1 mM EDTA 
 
5 ml LB-medium was inoculated with a single colony and grown overnight at 37°C, 
170 rpm. 4.5 ml of this culture was harvested by centrifugation (15000 rpm, 4°C, and 
1 min) and resuspended in 200 µl buffer 1 by vortexing. The suspension was mixed 
with 300 µl buffer 2 by inversion and incubated on ice for 5 min. Then 300 µl buffer 3 
was added and incubated on ice for 5 min. After centrifugation for 10 min (15000 rpm, 
4°C), the supernatant was transferred into a fresh eppendorf tube. 300 ul phenol and 
300 ul chloroform were added to the supernatant, and centrifugated (15000 rpm, 4°C 
and 5 min) after mixture. The supernatant was transferred to a new EP tube and mixed 
with 600 ul chloroform and centrifugated again (15000 rpm, 5 min). After taking 
away the supernatant, DNA was precipitated by addition of equal volume of 
isopropanol and centrifugation (15000 rpm, 4°C and 10 min). DNA pellet was washed 
once with 500 µl 70% ethanol, dried under vaccum and resuspended in 20 µl TE 
buffer. 
 
All plasmid maximal preparations were carried out with Qiagen Plasmid Midi Kit 
according to the manual. 
 
2.6.3 Transformation of E. coli strains 
 
E. coli competent cells were prepared in the laboratory. XL1-Blue, MM294, Origami 
(DE3) and BL21 (DE3) cells were transformed by the heat-shock method: 50-100 ng 
plasmids DNA was mixed with 60-80 ul competent cells previously thawed on ice for 
approximately 10 min, and incubated on ice for 30 min. Subsequently, the mixture 
was subjected to heat shock at 42 °C for 90 seconds and put back on ice for 2 min. 
800 ul LB medium without antibiotics was added and the mixture was incubated at 
37°C for 60 min. After centrifugation at 4000 rpm for 5 min, 600-700 ul of 
supernatant was discarded, and bacteria resuspended in the remaining LB were plated 
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onto a selective LB plate and incubated overnight at 37 °C. 
 
2.6.4 Determination of DNA concentration and purity 
 
The concentration and the purity of double stranded plasmid DNA were determined 
based on the Beer-Lambert Law by measuring absorbance at 260 nm and 280 nm: 
A260 = ε260 c l and A260 x 50 = μg/ml (when l = 1 cm) 
A260 is the absorbance at 260 nm, ε260 is the molar absorption coefficient, c is the 
molar concentration and l is the optical path. For a protein-free and RNA-free solution 
of DNA the ratio of A260/ A280 should be close to 2. Protein contaminants would 
reduce the ratio, whereas RNA contamination would increase it. To further estimate 
the concentration and purity of DNA preparations, agarose gel electrophoresis was 
carried out. 
 
2.6.5 Molecular cloning of VWC domains and mutants 
2.6.5.1 Cloning of CV2-VWC domains 
 
cDNA of VWC1 amplified by recombinant PCR was inserted into the modified 
pET32a vector at XbaI and Bpu1102I sites (Fig. 2.1A). Other VWC domains were 
cloned into plasmid pET32a at NcoI and Bpu1102I sites (Fig. 2.1B). Plasmids 
containing VWC domains were transformed into MM294 for plasmid propagation. 
DNA minimal preparation followed by enzyme digestion was performed to select the 
positive clones. DNA maximal preparation was used to isolate plasmid DNA for 
sequencing (performed by the Department of Humangenetic, Biocenter of the 
University of Wuerzburg). Positive plasmids were transformed into host cell Origami 
(DE3) for protein expression.  
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Figure 2.1. A: Expression vector of pET32a-[Thr-CV2-VWC1] B: Expression vector of pET32a-[Thr-CV2-VWC] 
domains. 
 
2.6.5.2 Cloning of CV2-VWC1 mutants  
 
PCR products of CV2-VWC1 mutants were amplified by recombinant method and 
cloned into pET32a at NcoI and Bpu1102I sites (Fig. 2.2). Clones were transformed 
into MM294 for DNA propagation. Positive clones were transformed into Origami 
(DE3) for protein expression.  
 
Figure 2.2. Expression vector of pET32a-[Thr-CV2-VWC1] mutants. 
A B 
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2.6.5.3 Cloning of multi-VWC fragments 
 
Multi-VWC fragments were amplified by recombinant PCR and cloned to 
pACGP67b/TH trasfer vector at EcoRV and BamH1 sites. Clones were co-transfected 
with BaculoGold DNA into SF9 cells for protein expression. 
 
 
Figure 2.3 Map of the transfer vector of pACGP67B containing CV2-VWC domains. 
2.7 Expression of proteins 
2.7.1 Expression of thioredoxin fusion proteins in TB-Medium 
 
TB-Medium:  13.3 g/l Tryptone; 26.6 g/l Yeast Extract; 4.4 ml/l Glycerin  
80 ml 10 × Pi added to 720 ml TB-Medium before use  
10x Pi:    0.17 M KH2PO4, 0.72 M K2HPO4 
Wash buffer:  20 mM Tris/HCl; pH 7.5; 150 mM NaCl 
 
A single clone was inoculated into 2 ml TB medium containing appropriate antibiotics 
and grown at 37°C for 8 h. This pre-culture was used to inoculate a new 120 ml TB 
culture which was left to grow at 37°C for 15-17 h. Bacteria from 40 ml cultures was 
added to 800 ml TB medium, which were shaked at 30°C, 150 rpm, until they reached 
an OD600 of 0.6. 0.8 ml of 1 M IPTG was added for protein induction, and the cultures 
were left to grow for 15 h-17 h at 20°C, 120 rpm. The bacteria were then harvested by 
Material and Methods 
 - 33 - 
centrifugation at 4°C for 10 min, 6000 rpm, and washed by resuspension in the wash 
buffer followed by centrifugation. The bacteria pellets were stored at –20°C until next 
step.  
 
2.7.2 Expression of 15N labelled and 15N13C labelled thioredoxin fusion 
CV2-VWC1 
 
M9 minimal medium:  
10× M9:  60 g Na2HPO4; 30 g KH2PO4; 5 g NaCl; add 1000 ml dH2O; pH 7.2 
– 7.4; autoclaved   
1000x MgSO4:  1 M MgSO4 x 7 H2O; autoclaved  
1000x CaCl2:  1 M CaCl2 x 2 H2O; autoclaved  
100x  
Trace elements: 5 g EDTA; 0.8 g FeCl3; 0.05 g ZnCl2; 0.01 g CuSO4; 0.01 g CoCl2; 
0.01 g H3BO3; 1.6 g MnCl2 x 6 H2O; 0.01 g Na2MoO4 x 2 H2O; 
adjust to 1000 ml, pH 8.0; sterile filtration, dark keeped  
100x Glucose: 40 g Glucose/100 ml dH2O; sterile filtration  
100x13C-Glucose: Powder 
1000x Thiamin: 50 mg Thiamin HCl/ml dH2O; Freshly prepared, sterile filtration, 
freshly use 
500x 15N-NH4Cl: 0.25 g 15N-NH4Cl/ml dH2O 
 
E. coli strain BL21 (DE3) was used for the expression of 15N-labelled 
thioredoxin-fusion VWC1. A single clone was inoculated into 2 ml LB medium 
containing ampicillin (100 mg/L) for 8 h at 37°C, 170rpm. After culture, the 2 ml LB 
medium was transferred to 120 ml 15N-labelled M9 minimal medium with ampicillin 
(100 mg/L), and cultures were grown at 37°C for 15-17 h. 40 ml bacteria from them 
was added to 800 ml 15N-labelled M9 minimal medium containing ampicillin (100 
mg/L) and the cultures were shaked at 30°C, 150 rpm. When OD600 reached 0.6, 0.8 
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ml of 1 M IPTG was added to the medium to induce the protein expression. The 
culture was grown at 20°C, 120 rpm, for 15 h-17 h. Bacteria were harvested by 
centrifugation (10 min, 6000 rpm) and washed by resuspension in the wash buffer 
followed by centrifugation. The bacteria pellets were stored at –20°C until next step. 
The expression of 15N13C-labelled fusion protein Thr-CV2-VWC1 was performed 
similar to the expression of 15N-labled protein, except that 0.8g 13C-Glucose was 
added to the 15N-labelled M9 minimal medium without Glucose 10 min later after the 
adding of 1M IPTG.  
 
2.7.3 Selenomethionine labelled thioredoxin fusion CV2-VWC1 and mutants 
 
Selenomethionine labelled thioredoxin fusion CV2-VWC1 and mutants were 
expressed in the E. coli strain BL21 (DE3). A single clone incubated in 2 ml LB 
medium containing ampicillin (100 mg/L) was grown at 37°C 170 rpm, for 6 h, and 
then transferred to 120 ml M9 minimal medium containing ampicillin (100 mg/L), 
which was shaked at 37°C, 120 rpm for 15-17 h. 40 ml medium from the cultures was 
added to 800 ml M9 minimal medium containing ampicillin (100 mg/L), shaked at 
30°C, 150 rpm until its OD600 reached to 0.4. At this point Selenomethionine (50 mg) 
along with lysinehydrochloride (100 mg), threonine (100 mg) phenylalanine (100 mg), 
leucine (50 mg) isoleucine (50 mg) and valine (50 mg) were added as solide. After 
about 1 h of shaking, 0.8 ml 1 M IPTG was added, and the cultures were grown with 
shaking at 20℃ 120 rpm, for 15-17 h. The bacteria were harvested by centrifugation 
at 4°C for 10 min, 6000 rpm (JA-30), and washed by resuspension with wash buffer 
followed by centrifugation. The bacteria pellets were stored at –20°C until next step. 
The percentage of incorporation of selenomethionine was determined by mass 
spectrometry. 
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2.7.4 Expression of proteins in SF9 cells 
 
The plasmid cDNA encoding target proteins was cotransfected into SF9 cells 
according to Co-transfection method. Then Plaque-assay was performed according to 
standard method to get single virus clone. 
 
Single virus clones were picked up with 100 ul pipette tips, transferred into 1 ml cell 
culture medium and incubated at 27°C for 1h. Then the mediums containing virus 
were subjected to centrifugation at 1000 rpm for 5 min at RT to remove the agarose 
debris. The supernatants were planted to a 6–well plate with each well having 1.5 × 
106 SF9 cells, then the plate was incubated at 27°C for 4 days for the first virus 
amplification. 
 
The virus solution from the first virus amplification was centrifugated at 1000 rpm for 
5 min at RT, and then the supernatant was planted to a 6-well plate with each well 
having 1.5 × 106 SF9 cells and 1 ml medium. The plate was incubated at 27°C for 4 
days for the second virus amplification. 4 days later, 10 ul virus solution was taken 
from every well and subjected to western blot to test positive expression.  
 
The positive virus solution from the secondary amplification was centrifugated at 
1000 rpm for 5 min at RT, and then the 2 ml supernatant was added to flasks (175 cm2) 
with 80% SF9 cells confluence in 35 ml medium. Subsequently the flasks were 
incubated at 27°C for 4 days for the fourth virus amplification. 4 days later, the virus 
titers were determined by Plaque-assay to ensure that the titers were above 5 × 107 
virus/ml.  
 
After the fourth virus amplifications, 10-20 ml high titer virus solution containing at 
least 9x108 virus was added to roller-bottle having 200 ml medium with 1.5 × 106 
cells/ml, which was incubated at 27°C for 4 days for protein expression.  
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Co-transfection: 
When grew to 90% confluence, the SF9 cells were suspended by hand-shake in new 
medium and adjusted to a cell density of 0.8 × 106 cells/ml. 1 ml cell-suspension was 
transferred to each well of a 6-well plate and supplemented with additional 1 ml SF9 
medium. The plate was incubated for 1 h at 27°C to let cells attach to the surface of 
the plate. Afterwards, the medium was removed from the wells and 500 ul transfer 
buffer A was added to each wells. DNA mixture was prepared by mixing 1.5 ug 
recombinant plasmid with 2.5 ul Baculo-Gold DNA and incubating it at 20°C for 5 
min, and then adding 500 ul transfer buffer B. The mixture was slowly pipetted to the 
cells, and was incubated for 4 h at 27°C. Then the cells was washed for 2 times with 
1.5 ml SF9 cell medium, and then incubated cells for 4-5 days at 27°C.  
 
Plaque-assay: 
After grown to 90% confluence, the SF9 cells were suspended by hand-shake in new 
medium and adjusted to a density of 0.8 × 106 cells/ml. 1 ml cell suspension was 
added to every well of a 6-well plate and supplemented with additional 1 ml SF9 
medium. Afterwards the plate was incubated for 1h at 27°C. During this period, the 
virus solution was collected from the co-transfection experiment and diluted stepwise 
into different concentrations: 10-1, 10-2, 10-3, 10-4, 10-5, 10-6, 10-7, and 10-8. Then the 
medium from the 6-well plate was removed and the virus dilution (10-3, 10-4, 10-5 and 
10-6) was added to each well of the plate and incubated at 27°C for 1h. After 1h, the 
medium was removed and 1.5 ml agarose mixture, which was fleshly prepared by 
mixing 3.5 ml 2.7 % agarose with 700 ul fetal calf serum and 6.6 ml 2×Xpress 
medium, was added to every well of the plate. Following the solidification of the 
agarose, the plate was wrapped with parafilm and stored it on top of wet papers, and 
lay inside a box at 27°C for 5 days. 
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2.8 Purification of proteins  
2.8.1 Bacteria sonication 
 
Sonication buffer: 20 mM Tris/HCl; pH 7.9; 500 mM NaCl; 5 mM Immidazol 
1 mM PMSF 
Ultrasonic:   System 585, Ultratransducer 512/1204 (KLM) 
Super centrifuge: Super centrifuge L8-70M, 45Ti-Roter (Beckman) 
 
8-12 g bacteria stored at -20°C was defrosted in 4°C and resuspended in 200 ml 
sonication buffer. Sonication was performed for 30 s at 300 W for 10 times in a glass 
cup with a 10 min-cooling interval. Afterwards solution was centrifugated at 30,000 
for 30 min at 18°C. The resultant supernatant containing soluble thioredoxin fusion 
protein was collected for the Ni-chelating chromatography. 
 
2.8.2 Nickel-chelating chromatography 
 
Loading buffer:   20 mM Tris/HCl; pH 7.9, 500 mM NaCl, 5 mM Immidazole 
Wash buffer:  20 mM Tris/HCl; pH 7.9, 500 mM NaCl, 60 mM Immidazole 
Elution buffer:  20 mM Tris/HCl; pH 7.9, 500 mM NaCl, 500 mM Immidazole 
Precolumn material: Sephacryl S-100 (Pharmacia) 
Column material: Chelating Sepharose FF (Pharmacia) 
Pump:    Minipuls 3 (Gilson) 
Detector:   2238 Uvicord II (LKB Bromma) 
 
The Ni-chelating column was stored in 250 mM EDTA at 4 ºC. Before use, the 
column was washed by 100 ml ddH2O to remove the EDTA, and then 100 ml 50 mM 
NiCl2-solution was loaded to it followed by an equilibration with 100 ml loading 
buffer. The supernatant was load through a connected precolumn to the Ni-chelating 
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column. Afterwards the column was first washed with loading buffer, followed by 
wash buffer to remove the contaminated proteins from E. coli. Proteins bound to the 
column were eluted by elution buffer and collected every 7 min for 1 fraction in a 
collector. The Ni-chelating column was washed with 250 mM EDTA to remove the 
Nickel-ions. Proteins collected from every fraction were analysed in a SDS-PAGE and 
dialysed against 5 L buffer for Thrombin cleavage at 4 ºC. 
 
2.8.3 Ni-NTA chromatography 
 
Loading and Wash buffer: 50 mM NaH2PO4, pH 8.3, 10 mM Imidazol, 300 mM NaCl 
Elution buffer:     50 mM NaH2PO4, pH 8.3, 300 mM Imidazol, 300 mM NaCl 
 
Cell suspension was centrifugated at 10000 rpm for 15 min (GSA-10a, 4 ºC). The 
supernatant was dialysed for two times against 10-fold volumes of loading buffer at 4 
ºC for 6-8 h. The supernatant was centrifugated again after dialysis at 10000 rpm for 15 
min (GSA-10a, 4 ºC). 5 ml Ni-NTA resin was equilibrated by wash buffer, mixed with 
the supernatant and then stirred for 1h at 4 ºC. Mixture was transferred to the column 
cartridge and washed with 5 beads volumes wash buffer. Proteins bound to the Ni-NTA 
column were eluted with about 50 ml elution buffer.  
  
2.8.4 Anion and cation exchange chromatography 
 
Loading buffer:  20 mM Tris/HCl, pH 7.4 
Elution buffer:  20 mM Tris/HCl, pH 7.4; 1 M NaCl 
Column material: Fractogel EMD TMAE 650 (S) (Merck, Darmstadt) 
     SP-sepharose (Merck, Darmstadt)               
Column:    Super performance 10 (Merck, Darmstadt) 
Pump:     L6200 intelligent pump (Merck/Hitachi) 
Detector:    L-4200 UV-VIS (Merck/Hitachi) 
Collector:    FC 203B (Gilson) 
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Protein separation by ion exchange chromatography depends on the reversible 
adsorption of charged molecules to an immobilized ion exchange group of opposite 
charge. Various conditions such as ionic strength and pH could influence these 
interactions. To ensure electrostatic binding, the total ionic strength needs to be low.  
 
The columns for anion exchange chromatography or cation exchange chromatography 
were equilibrated with 5 column volumes of loading buffer. Then the sample was 
loaded (flow rate 1.5 ml/min) and washed until baseline was reached in the recorder. 
The elution was performed with a linear gradient of NaCl concentration (flow rate 1 
ml/min) as shown in Table 2.2. Proteins were collected in a way of tube/1.5 min. 
Eluted fractions containing the protein of interest were pooled. CV2-VWC1 was 
purified by TMAE column, and the other four VWC domains were purified by 
SP-sepharose column.  
 
Table 2.2 Purification procedure of CV2-VWC domains by TMAE column or Sp-sepharose column. 
 
 
2.8.5 High Performance Liquid Chromatography (HPLC) 
 
Loading buffer:  0.1 % (v/v) TFA in ddH2O 
Elution buffer:  100 % Acetonitrile (ACN) 
Analytic column: Vydac-214TP; C4; 10 µM; 46 x 250 cm (MZ-Analysentechnik) 
Semiprep column: Vydac-214TP; C4; 10 µM; 80 x 250 cm (MZ-Analysentechnik) 
Pump:    L6200 intelligent pump (Merck/Hitachi) 
Detector:   L-4200 UV-VIS (Merck/Hitachi) 
Collector:   FC 203B (Gilson) 
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The capacity of the analytic HPLC column is maximal 2 mg protein, and maximal 30 
mg protein for the semiprep column. Columns were first washed with 100% 
Acetonitrile, and then equilibrated with 0.1 % TFA buffer. The sample was mixed in a 
ratio of 1:1 with 0.1% TFA to make the pH value less than 4.0. After loading the 
samples, the column was washed until baseline was reached in the recorder. The 
elution was performed with a linear gradient of ACN concentration (flow rate 0.7 
ml/min for analytic column and 2 mg/ml for the semiprep column). VWC domains 
were eluted at 26% -27% Acetonitrile (Table 2.3). 
 
Table 2.3 Gradients of reverse phase HPLC in analytic and semiprep column. 
 
 
  
2.8.6 Gel filtration chromatography 
  
Loading buffer:  10 mM Hepes, pH 7.4; 700 mM NaCl 
Column material: Superdex 200 HR 10/30 (Pharmacia) 
Pump:     L6200 intelligent pump (Merck/Hitachi) 
Detector:    L-4200 UV-VIS (Merck/Hitachi) 
Collector:    FC 203B (Gilson) 
 
On a gel filtration (or size exclusion) column the molecules are separated based on the 
differences of their sizes. Column was equilibrated with two column volumes (50 ml) 
loading buffer and the concentrated protein solution (less than 500 ul) was injected 
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into a 10 ml loop with an injection needle (Rothe). Flow rate was 0.5 ml/min and 
fractions were collected 1 tube/min. Small molecules that can diffuse into the pores of 
the gel beads are delayed in their passage through the column in contrast to the larger 
molecules, which cannot diffuse into the gel beads. The larger molecules thus leave 
the column first, followed by the smaller ones in order of their sizes. Gel filtration was 
performed with a Superdex 200 HR 10/30 column (Pharmacia). 
 
2.8.7 Calibration of the superdex 200 column 
 
Calibration of Superdex 200 HR 10/30 allows the estimation of protein molecular 
weights to obtain a calibration curve. The eluant was monitored by a UV detector at a 
wavelength of 280 nm. Bovine serum albumin (66.4 kDa), Ovalbumin (43 kDa) and 
Ribonuclease A (13.7 kDa) were used to calibrate the column. 
 
The void volume of the column was determined using Blue Dextran 2000. The Kav 
for individual protein was calculated as follows:  
Kav = (VR - V0)/(Vc - V0) 
 
V0= void volume of the column 
VR = retention volume of the protein  
Vc = the geometric bed volume in ml.  
 
 
Material and Methods 
 - 42 - 
 
Figure 2.4 Calibration curve of superdex 200 HR 10/30 column.  
 
A plot of Kav versus log MW for a standard run resulted in a straight line with a 
correlation coefficient R2 = 0.99 (Fig 2.4). Linear regression gave the equation 
logMW = - 2.5524×Kav + 5.6528. This equation was used to calculate the apparent 
molecular weight of the proteins separated by the column. 
 
2.8.8 BMP-2 affinity chromatography 
 
Running buffer:   10 mM Hepes pH 7.5, 500 mM NaCl 
Elution buffer:   4 M MgCl2 
Column keeping buffer: 10 mM Hepes pH 7.5, 150 mM NaCl 
Column material:  20 mg BMP-2 bound to 10 mg Cyanbromid-activited 
Sepharose (Pharmingen) 
Pump:     Minipuls 3 (Gilson) 
Detector:     2238 Uvicord II (LKB Bromma) 
 
The whole procedure was performed at 4 ºC. Proteins were separated based on their 
interaction with BMP-2 proteins. Proteins that had no binding for BMP-2 flew 
through BMP-2 affinity column and were separated from proteins binding to the 
column. The BMP-2 column was first equilibrated with 5 column volumes loading 
buffer (HBS500), then the sample was loaded and washed until baseline reached in the 
recorder to make sure proteins unspecifically bound to the column flew through it. 
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Afterwards elution step was performed with 4 M MgCl2 with a collected fraction of 
tube/6 min. After the elution, the BMP-2 affinity column was washed by 10 mM 
Hepes pH 7.5, 150 mM NaCl buffer to get rid of MgCl2, and kept at 4°C.  
 
2.9 Thrombin cleavage 
 
Buffer for thrombin cleavage: 50 mM Tris/HCl pH 7.5; 150 mM NaCl, 2.5 mM 
CaCl2   
Thrombin solution: 8.0 g thrombin (Sigma), 600 ul buffer for 
thrombin-cleavage, 600 ul Glycerine  
 
Thioredoxin-fusion proteins were dialysed against the thrombin cleavage buffer 
overnight and centrifuged at 4°C, 5000 rpm for 10 min. Thrombin was then added 
(2-4 ug of thrombin per mg fusion protein) and the cleavage was performed at 30°C 
for 3 h. Centrifugation was performed afterwards to remove the precipitant proteins. 
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2.10 Protein chemistry methods  
 
2.10.1 Proteins marker (Biofermentas): 
 
 
 
2.10.2 SDS-Polyacrylamid-Gelelektrophorese (SDS-PAGE) 
 
AA/BAA-solution:   30% Acrylamide; 1% N,N´-Methylenbisacrylamide 
4X Lower Tris:    1.5 M Tris/HCl; pH 8.8; 0.4% SDS 
4X Upper Tris:    0.5 M Tris/HCl; pH 6.8; 0.3% SDS 
SDS-Running bufferr:  25 mM Tris/HCl; pH 8.6; 0.19 M Glycin; 0.15% SDS 
SDS-Loading buffer:  62.5 mM Tris/HCl; pH 6.8; 2% SDS; 20% Glycerin; 2% 
Bromophenol blue in H2O; (for reduced conditions: add 2% 
2-Mercaptoethanol) 
 
Table 2.4 is a summary of the solutions for one SDS-PAGE gel. After adding the 
separating gel, 1.5-2 cm space was filled with H2O. When the separating gel was 
solid, the water was suck out and stacking gel was filled. Protein samples were diluted 
1:1 with SDS-PAGE loading buffer, and heated for 3 min at 100 °C. Electrophoresis 
was carried out at 175 V and maximal 35 mA in SDS-PAGE running buffer.  
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Table 2.4: Solutions for preparing SDS-PAGE gel. 
 
        
2.10.3 Coomassie Brilliant Blue staining  
 
Coomassie Brilliant Blue staining solution:  
6.25 g Coomassie Brillant Blue R250; 0.25 L Acetid acid; 1L Methanol; 1.25L dH2O 
Destaining buffer:  Isopropanol: Acetid acid: dH2O 1:1:8 
Protein fixing buffer:  30% methanol. 
 
The gels were stained in Coomassie Brilliant Blue R250 solution for 20 min on a 
shaking platform. Next, the gels were destained in the destaining solution. For long 
time storage, the gels after destained were incubated in 30% methanol for a minimum 
of 20 min and sealed with 2 layers Cell membranes and kept at room temperature.  
 
2.10.4 Silver staining  
 
Solution 1:   50% (v/v) acetone in dH2O; 0.75 ml 50% (w/v) TCA in dH2O; 
12.5 µl 37% Formaldehyde. 
Solution 2:   30 ml 50% (v/v) Aceton in dH2O 
Solution 3:   50 µl 10% (w/v) Na2S2O3 • 5 H2O in dH2O; 30 ml dH2O 
Solution 4:   0.4 ml 20% AgNO3 in dH2O; 0.3 ml 37% Formaldehyde; 30 ml dH2O 
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Solution 5:  0.6 g Na2CO3; 12.5 µl 37 % Formaldehyd; 12.5 µl 10 % (w/v) 
Na2S2O3 • 5 H2O; 30 ml dH2O 
Solution 6:  1% (v/v) Glacial Acetic Acid 
 
One gel was incubated in solution 1 for 5 min and washed 3 times with water, and 
then put to solution 2 for 5 min and then solution 3 for 1 min. Subsequently put the 
gel to solution 4 for 8 min after washed 3 times in H2O. After washing, put gel to 
solution 5 for about 30 seconds for staining, and then transfer solution 6 to solution 5 
to stop the staining. Wash the gel again with water and put to 30% methanol for 
keeping.  
 
2.10.5 Concentrating the protein solution 
 
The protein solutions were concentrated using the Amicon® Ultra-4 Centrifugal Filter 
Units (Millipore). In this device, a membrane with a molecular weight cut-off lower 
than that of the interested protein is placed at the bottom of a cell, which is filled with 
the protein solution. The cell is then placed in a 15 ml falcon tube and centrifuged at 
less than 4000 rpm. In this manner, the flow-through solution contains only lower 
molecular weight components, while the protein is concentrated in the chamber. 
 
2.10.6 Determination of the protein concentration 
 
We used measurement of UV absorbance at 280 nm to determine protein 
concentration. Quartz cuvets or cuvettes that are known to be transparent to 280 nm, 
filled with a volume of solution sufficient to cover the aperture through which the 
light beam passes. The protein solution must be diluted in the buffer to a 
concentration that is well within the accurate range of the instrument. The protein 
solution to be measured can be in a wide range of buffers. At low concentrations, 
protein can be lost from solution by adsorption on the cuvette; the high ionic strength 
helps to prevent this. The value obtained will depend on the path length of the cuvet. 
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If not 1 cm, it must be adjusted by the appropriate factor. The Beer-Lambert law states 
that: A (Absorbance) =  Ê.c.l 
where Ê = extinction coefficient, c = concentration in mol/L and l = optical path 
length in cm. Therefore, if Ê is known, measurement of A gives the concentration 
directly, e is normally quoted for a 1-cm path length. 
  
2.10.7 Biosensor interaction analysis  
 
System:   Biosensor BIAcore 2000TM (BIAcore)  
HBS –Puffer: 10 mM HEPES, pH 7.4; 500 mM NaCl; 3.4 mM EDTA, 0.05% P20 
 
The BIAcore 2000 system (Amersham Biosciences) was used for all biosensor 
experiments in this thesis. A CM5 biosensor chip was first loaded with streptavidin in 
flow cells 1, 2, 3 and 4, and subsequently biotinylated proteins were immobilized at 
the streptavidin matrix of flow cell 2, 3 and 4 at a density of about 200 resonance 
units (RU) or 400-600 RU depending on the affinity of the interaction. The proteins 
for perfusion were diluted with HBS running buffer (10 mM HEPES, pH 7.4/500 mM 
NaCl/3.4 mM EDTA/0.005% surfactant P20) and applied at concentrations between 
10 and 1000 nM. Flow rates were set to 10 µl·min-1 at 25°C, flow path was 1-2-3-4, 
and data were recorded at 2.5 Hz. Sensorgrams were evaluated on the basis of a 1:1 
association model according to fitting routines 2 or 3 provided by the BIA evaluation 
2.1 software (Amersham Biosciences). For dissociation constants (KD ) < 50 nM, 
kinetic constants (kon and koff) were evaluated. For KD values > 50 nM, 
dose-dependent equilibrium binding was evaluated. KD values or rate constants koff/kon 
was evaluated from one experiment determined for 6 to 9 different concentrations of 
the analytes. Mean values of KD and their standard deviations (SD) were calculated 
from the values of at least three different experiments. Standard deviations for the 
obtained affinities were less than 50%. For the comparison of the wt CV2-VWC1 and 
mutants, differences between mean values of more than 2 x SD were considered 
significant. All Biosenser interaction analysis was performed by Dr. Jinli Zhang.  
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2.10.8 Mass spectrometry 
 
All mass spectrometry analysis of proteins performed with Electrospray Ionization 
Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (ESI-FTICR-MS) by 
Dr. Werner Schmitz. Mass spectrometry analysis was used to determine the molecular 
weights of stable fragment of CV2-VWC1 and selenomethionine-labelled proteins. 
  
2.10.9 Western blotting 
 
Transfer buffer:   25 mM Tris/HCl, 200 mM Glycine, 10% methnol 
Blocking and wash buffer: 3% milk, 10 mM Tris/HCl, 50 mM NaCl, 0.1% 
Tween-20  
Luminion solution:   2.5 mM Luminol in 0.1 M Tris/HCl pH 8.5, 1% DMSO 
Enhancer solution:    90 mM p-Cumarsaure in DMSO 
H2O2 solution:     5.4 mM in 0.1 M Tris/HCl pH 8.5 
 
Transfer proteins to a membrane 
(1) Run an SDS-PAGE, and then transfer the proteins from SDS-PAGE to the 
nitrocellulose membrane for 60 min at 150V.  
 
Antibody incubation  
(2) Incubate the blot with 10 ml blocking buffer for 1h at room temperature with 
gentle agitation. Dilute first antibody (1:1000-2000) in 10 ml of blocking buffer and 
incubate the blot with the primary antibody for 1h at room temperature. 
(3) Wash the blot 3 times, 10 minutes each, in washing buffer with gentle agitation to 
get rid of the first antibody.  
(4) Dilute second antibody (1:5000-10000) in 10 ml of blocking buffer and incubate 
the blot with second antibody for 1h at room temperature. 
(5) Wash the blot 3 times, 10 minutes each, in washing buffer with gentle agitation. 
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Luminol detection 
(6) Drain wash buffer, and then add mixture of 5 ml Luminol solution, 22 ul enhancer 
solution and 5ml H2O2 solution, incubate for 2-3 min in a dark room.  
(7) Drain the fluid and cover the blot in plastic wrap and put 3 X-ray films on it. 
Expose the blot to X-ray film for 5 min in dark room.  
 
2.11 Crystallization solutions and methods 
2.11.1 Crystallization solutions 
 
Crystallization screens purchased from Hampton Research: 
 
Crystal screen 1     Additive screen 1 
Crystal screen 2     Additive screen 2 
Crystal screen Index    Additive screen 3  
SaltRx screen     Crystal screen Lite 
                  
2.11.2 X-ray Crystallization of BMP-2 and CV2-VWC1 complex 
 
Crystallization experiments were carried out with Sitting Drop Vapour Diffusion 
technique for crystal initial screening and Hanging Drop Vapor Diffusion method for 
crystal optimization. CrystalQuick 96 wells were used for Sitting Drop Vapour 
Diffusion technique and 24 wells reservoir plates were used for Hanging Drop Vapor 
diffusion method. The detailed procedure for Hanging Drop Vapor diffusion method is 
as follows: Using a clean pipet tip, pipet 1 ml of each crystal screen reagent into 
reservoirs, and took 1 µl buffer of the reagent and mixed with 1 µl of complex protein. 
Applied the 2 ul mixture to the thin bead of cover slide sealant to the upper edge of 
each of the reservoir. Regarding the Sitting Drop Vapor diffusion method, we pipeted 
100 ul of each crystal screen reagent into wells, and the mixture of 1 ul of the 
complex protein and 1 ul buffer was set in the middle of the reservoir, finally sealed 
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the whole plate by tape. Crystallization setup was performed in duplicate and 
incubated at 20°C for several weeks in a stable temperature environment, free of 
vibration. The drops were observed under a stereo microscope (10 to 100 x 
magnification) once each day for the first week, then once a week for the following 
three weeks.  
 
2.11.3 Cryoprotection of crystals 
 
Cryocooling techniques are routinely used in macromolecular crystallography to 
preserve crystals and reduce radiation damage during X-ray data collection. 
 
The high intensity of synchrotron radiation can lead to radiation damage of the protein 
crystals. The interaction between the beam and the crystal generates thermal disorder 
and may even break bonds within the protein. A common method to prevent this 
radiation damage was to freeze the crystals in a stream of cold nitrogen and collects 
the diffraction data at low temperature (93). But the high solvent content (~50%) of 
protein crystals can lead to ice crystal formation during freezing and these ice crystals 
will destroy the crystal integrity and disturb the protein diffraction. This problem can 
be overcome by soaking the crystal in a cryoprotectant solution that maintains the 
crystal quality and prevents the formation of ice crystals (93). Binary complex of 
BMP-2 and CV2-VWC1 crystals were soaked in different cryoprotecting agents like 
glycerol, sucrose and glucose and tested for the diffraction quality. 
 
2.12 Biological Activity in Cell Lines 
 
Alkaline phosphatase (ALP) activity was determined in serum-starved C2C12 cells. 
The promyoblast C2C12 cells (ATCC CRL-1772) were stimulated at a density of 3 
104 cells/well in a 96-well microtitre plate for 3 days with 0.5–250 nM of each BMP-2 
variant in 100 ul of Dulbecco's modified Eagle's medium (DMEM) containing 2% calf 
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serum and antibiotics (100 U/ml penicillin G and 100 ug/ml streptomycin) at 37°C in 
a humidified atmosphere at 5% CO2. Cells were washed with phosphate-buffered 
saline (PBS) and then lysed for 1 h with 100 ul of 1% NP-40 in ALP buffer (0.1 M 
glycine, pH 9.6, 1 mM MgCl2, 1 mM ZnCl2). ALP activity was determined by 
incubating lysed cells for 15 min with 100 ul of ALP buffer plus 1 mg/ml 
p-nitrophenylphosphate, and measuring the extinction at 405 nm. One A405 extinction 
unit corresponds to 1.5 nmol of p-nitrophenolate produced per min per 3 104 cells. 
Inhibition of BMP-2-induced ALP activity by CV2, CV2-VWC1 and CV2-VWC1 
mutants were assessed by incubating C2C12 cells with different concentrations of 
them plus 10 nM BMP-2. Relief of CV2 inhibition of BMP-2-induced ALP activity 
was assessed by incubating C2C12 cells with 10 nM BMP-2 plus CV2 and increasing 
concentrations (6.3-25 nM for CV2) of BMP-2 mutants. Results are given as mean 
values from six determinations done in parallel for each condition.   
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3.  Results 
3.1  Preparation of VWC domains of CV2 
3.1.1 Expression and purification of CV2-VWC1 domain  
 
Cloning and expression of zCV2-VWC1 fusion protein 
In a previous study the binding properties of zebrafish CV2 (zCV2) and its fragments 
to human BMP-2 have been investigated. Results showed that the zCV2 binds human 
BMP-2 with the same binding affinity as human CV2 (hCV2) (78). For further 
structural analysis, we initially expressed hCV2-VWC1 and zCV2-VWC1 in parallel. 
The hCV2-VWC1 could be induced as a thioredoxin fusion protein in E. coli, but no 
soluble hCV2-VWC1 could be isolated after removing thioredoxin by protease 
cleavage. In contrast, native zCV2-VWC1 could be easily isolated with very high 
yield (see below). Thus, the zCV2 was used in all the experiments in this thesis.  
 
The cDNA encoding the residues 1-66 of mature zCV2 (Swiss-prot entry Q5D734) 
plus an N-terminal GSW extension was amplified by a recombinant PCR and cloned 
into a derivative of expression vector pET-32a (+) at the XbaI and Bpu1102I 
restriction enzyme sites. The expression plasmid pET32a [Trx-CV2-VWC1] (Fig. 
3.1A) that contains VWC1, thioredoxin, 6x histidine-tag and a Thrombin cleavage site 
was transformed into E. coli strain Origami (DE3). The encoded protein was 
expressed as a soluble thioredoxin fusion protein. 
 
    
A 
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Figure 3.1A amino acids sequence of CV2-VWC1. B Induction of the fusion protein Thr-CV2-VWC1 under 
non-reducing (NR) and reducing conditions (R). Lane M, Protein marker; Lane 1 and 3, uninduced bacteria; Lane 
2 and 4, induced bacteria  
  
The calculated molecular weight of Trx-CV2-VWC1 was 21.15KD, but it migrates 
anomalously at about 26KD under reducing condition and about 23KD under 
non-reducing conditions, both of which were higher than its theoretical molecular 
weight (Fig. 3.1B). We could obtain 3.0-3.8 g bacteria per liter TB medium after 
fermentation.  
 
Sonication, Ni-chelating chromatography and Thrombin cleavage 
8-15 g cell pellet was suspended and sonicated in 200 ml sonication buffer. The 
soluble fusion protein Trx-CV2-VWC1 was in the supernatant after sonication and 
centrifugation. As an initial purification step, Immobilized Metal Affinity 
Chromatography (IMAC) with Ni-chelating agarose was used to purify the fusion 
protein. After the Ni-chelating chromatography, the majority of the unspecific proteins 
were removed and the target protein could be eluted with a high concentration of 
imidazole (Fig. 3.2, lane 5-7). Yields of the purified fusion proteins were usually in 
the range of 25-32 mg per gram-wet bacteria. 
 
Figure 3.2 Expression and purification of thioredoxin 
fused CV2-VWC1. SDS-PAGE under reducing 
conditions show the expression and Ni-chelating 
chromatography results: lane 1, uninduced bacteria; 
lane 2, induced bacteria; lane 3, supernatant after 
centrifugation of the sonicated bacteria, lane 4, 
flow-through of the column washed with a buffer 
containing 60 mM column; lane 5-7, fractions eluted 
by a buffer containgng 500 mM imidazole. 
B 
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As shown in Fig. 3.2 lanes 5-7, the histidine-tag proteins could be purified by 
Ni-chelating chromatography. These proteins were then applied to subsequent 
Thrombin-cleavage. SDS-PAGE showed that CV2-VWC1 was efficiently cleaved 
from thioredoxin and the histidine-tag after thrombin treatment. The band of 
CV2-VWC1 protein migrates at 17 and 19 kDa in the SDS-PAGE under both 
reducing and non-reducing conditions, respectively, more than twice that computed 
from the protein sequence (7.3 kDa). There are still some uncut proteins which may 
represent incorrectly folded or multimer fusion proteins insensitive to thrombin (Fig. 
3.3). 
 
 
Anion exchange chromatography using TMAE column 
After cleavage of the fusion protein by Thrombin, the separation of CV2-VWC1 from 
thioredoxin and the histidine-tag was achieved by anion exchange chromatography 
using a EMD-TMAE column. The column was equilibrated in 20 mM Tris/HCl, pH 
7.4, and bound protein was eluted with a linear NaCl gradient from 0 to 1 M (Fig. 
3.4A). Fractions eluted from 60 mM-260 mM NaCl were subjected to SDS-PAGE. 
Fractions eluted from 100 mM-120 mM NaCl were shown to contain thioredoxin and 
CV2-VWC1 according to their molecular weight. Later fractions contain little VWC1, 
but mainly thioredoxin protein multimers and unspecific proteins (Fig. 3.4B). The 
proteins eluted with 60-120 mM NaCl were collected for further purification. 
 
Figure 3.3 SDS-PAGE analysis of fusion 
protein Thr-CV2-VWC1 cleaved by thrombin 
under reducing (R) and non-reducing (NR) 
conditions. M, protein markers; un-c, uncleaved 
fusion protein; c, fusion protein cleaved by 
thrombin.  
CV2-VWC1 
A 
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Figure 3.4 Purification of CV2-VWC1 after thrombin cleavage with TMAE column. The column was equilibrated 
with 20 mM Tris, pH 7.4 and eluted by the same buffer containing 0-1 M NaCL. A: Elution chart of proteins. B: 
SDS-PAGE analysis of proteins eluted with 60–260 mM NaCl under non-reducing conditions. F10-42 were 
collected as indicated in A. 
 
Reversed -Phase HPLC   
Reversed phase HPLC was sufficient to separate CV2-VWC1 from thioredoxin. 
CV2-VWC1 and thioredoxin were eluted separately with a linear Acetonitrile (ACN) 
gradient from 0-100%. There were 2 large peaks eluted by ACN on the chart, the first 
of which was very sharp and the corresponding proteins were eluted with 26% 
Acetonitrile, and the second with an ACN concentration higher than 80% (Fig. 3.5A). 
SDS-PAGE analysis showed that proteins from the second peak correspond to 
A 
B 
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thioredoxin and the histidine-tag (14 KDa), while CV2-VWC1 was in the first sharp 
peak based on its low electrophoretic mobility. The CV2-VWC1 protein was very 
homogeneous on the SDS-PAGE gel (Fig. 3.5B). After thrombin cleavage of the 
thioredoxin fusion protein, anion exchange chromatography and reversed phase 
HPLC, we could routinely obtain about 2-2.67 mg CV2-VWC1 per gram wet bacteria. 
  
 
 
Mass spectroscopy 
The identity of CV2-VWC1 was established by mass spectroscopy. Our result showed 
that no post-translational modified CV2-VWC1 or other unspecific proteins were 
found. The molecular weight of 7319.328 KDa measured by mass spectroscopy fitted 
very well with its theoretical value of 7319.295 KDa (Fig. 3.6). 
Figure 3.5 Purification of CV2-VWC1 with reversed phase 
HPLC column (0-100% Acetonitrile). A, Elution chart of proteins 
B, SDS-PAGE analysis of proteins purified by HPLC column 
under non-reducing condition. 
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Figure 3.6 A. Mass spectroscopy analysis of CV2-VWC1. B Deconvolution analysis of 6-fold-charged ions with 
corresponding molecular weight.  
 
BMP-2 affinity chromatography 
Although the CV2-VWC1 protein appears to be uniform on the SDS-PAGE after 
HPLC, the homogenous binding competent CV2-VWC1 could only be purified by 
means of BMP-2 affinity chromatography. The pure and active CV2-VWC1 could be 
used for the further NMR spectroscopy and crystallization. The BMP-2 affinity 
column was first equilibrated with 10 mM Hepes/500 mM NaCl, pH 7.4. Protein 
purified from the HPLC column was loaded and then the bound active VWC1 was 
eluted by 4M MgCl2. Finally the eluted proteins were dialyzed against 10 times 10 
mM Hepes/500 mM NaCl. SDS-PAGE showed that the CV2-VWC1 protein appears 
to be a smear under reducing condition and a sharp band under non-reducing 
condition (Fig. 3.7). There were about 10%-14% of proteins that might represent the 
not correctly folded CV2-VWC1 proteins could not bind to BMP-2 affinity column.  
 
 
Figure 3.7 SDS-PAGE analysis of BMP-2 affinity 
column purified CV2-VWC1 under reducing (R) and 
non-reducing (NR) conditions. 
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Table 3.1 Yields of CV2-VWC1 purification.  
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3.1.2 Expression and purification of CV2-VWC2, VWC3, VWC4 and VWC5  
 
Cloning and expression of CV2-VWC2, VWC3, VWC4 and VWC5 fusion 
proteins 
The cDNAs encoding zebrafish CV2-VWC2, VWC3, VWC4 and VWC5 were cloned 
into the derivative of expression vector pET-32a (same as mentioned above) at the 
NcoI and Bpu1102I restriction enzyme sites (Fig. 3.8). The expression plasmid 
pET32a that contains one of the VWC domains (domains 2 to 5), thioredoxin, 6x 
histidine-tag and a Thrombin cleavage site was transformed into E. coli strain Origami 
(DE3) and expressed as a soluble thioredoxin fusion protein.  
 
 
Figure 3.8 Amino acids sequences of CV2-VWC2, -VWC3, -VWC4 and –VWC5.  
 
The induction of the host E. coli cells with IPTG led to the production of the desired 
proteins (Fig. 3.9). The molecular weight of Trx-VWC2, VWC3, VWC4, and VWC5 
are 20.95, 22.57, 22.39 and 22.63 KDa, respectively, and their electrophoretic 
mobility in the SDS-PAGE were very closed to their theoretical molecular weights. 
We could get about 3.5, 12, 5 and12 g bacteria per liter TB medium, respectively. 
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Figure 3.9 Induction of the thioredoxin fusion proteins of CV2-VWC2 (1, 2), CV2-VWC3 (3, 4), CV2-VWC4 (5, 
6) and CV2- VWC5 (7, 8). Lanes 1,3,5,7 are samples of uninduced bateria control. Lanes 2,4,6,8 are samples of 
bacteria induced by 1 mM IPTG. 
 
Purification of fusion proteins Trx-CV2-VWC2, -VWC3, -VWC4 and -VWC5 
The 4 fusion proteins expressed in Origami (DE3) were isolated by standard 
procedures involving Ni-chelating chromatography, digested with thrombin, purified 
by TMAE or SP-Sepharose ion-exchange chromatography, and reversed phase HPLC 
column to apparent homogeneity. 
 
Ni-chelating chromatography was first used to roughly separate these four fusion 
proteins from endogenous E. coli proteins. The presence of disulfide bonds may 
sometimes cause improper folding in these products. Fig. 3.10 shows that most 
proteins purified after Ni-chelating chromatography were target proteins Thr-VWC2, 
-VWC3, and -VWC5 (with molecular weight between 20 kDa and 23 kDa). For 
Thr-CV2-VWC4, about 40% proteins migrated at 25 kDa which is close to the 
theoretical molecular weight. The other 60% migrated at 15 kDa which is similar to 
the molecular weight of thioredoxin plus 6x Histidine-tag. This is likely a truncated 
Thioredoxin-CV2-VWC4 which was processed in E. coli but still bound to 
Ni-chelating agarose (Fig. 3.10).  
 
Thrombin digestion could efficiently cleave most part of the Thr-CV2-VWC3 and 
VWC5 proteins. Thr-CV2-VWC2 seems to be partially digested as the cleaved 
thioredoxin was visualized after thrombin treatment. However, no clear VWC2 band 
could be found (Fig. 3.10, compare lanes 1 and 2, and lanes 3 and 4). Similarly, 
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Thr-CV2-VWC4 could be partially cleaved, but the single VWC4 band could not be 
clearly separated from that of thioredoxin, probably due to their similar mobilities in 
the SDS-PAGE. At this point, it was not clear whether VWC2 and VWC4 proteins 
could be isolated.  
 
 
 
Figure 3.10 SDS-PAGE analysis of fusion protein Thr-CV2-VWC2, -VWC3, -VWC4, and -VWC5 cleaved by 
thrombin under reducing and non-reducing conditions. M, protein markers; 1 and 3, uncleaved fusion protein; 2 
and 4, fusion protein cleaved by thrombin. 1 and 2 under reducing conditions; 3 and 4 under non-inducing 
conditions. 
 
Following a cleavage reaction, the 4 positively charged VWC domains could be easily 
separated from thioredoxin by cation-exchange chromatography employing a 
SP-Sepharose column (Fig. 3.11). The pI of VWC1, VWC2, VWC3 and VWC4 is 
8.87, 7.02, 6.95 and 9.02, respectively, and that of thioredoxin is 5.83. Therefore after 
loading of the protein mixture, thioredoxin was obtained in the flowthrough, while 
VWC domains bound and could be eluted by different NaCl concentrations. In the 
case of VWC3 and VWC5, very pure protein was obtained after SP-sepharose column, 
and the purity after such a separation usually exceeded 90%. In the case of VWC2 and 
VWC4, soluble proteins with similar apparent molecular weight can be detected. The 
target proteins were mixed with some unspecific proteins (dimers or multimers) that 
could not be easily separated by the SP-Sepharose column. 
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Figure 3.11 SDS-PAGE analysis of 4 VWC domains purified from the SP-sepharose column. M, protein markers; 
F, flow-through; Bf, samples before loading to the column. A, CV2-VWC2 eluted by 400 mM NaCl. B, 
CV2-VWC3 eluted by 330 mM NaCl. C, CV2-VWC4 eluted by 350 mM NaCl. D, CV2-VWC5 eluted by 450 mM 
NaCl.  
 
Although the 4 VWC domains could be effectively separated from thioredoxin by 
SP-Sepharose column, there were still a few unspecific proteins which remained (Fig. 
3.11). Reversed phase HPLC chromatography was then used to purify the proteins to 
apparent homogeneity (Fig. 3.12). The yield of the four VWC domains was not as 
high as that of VWC1. VWC2 and VWC4 yielded only 0.4 mg and 0.3 mg per liter 
TB medium, respectively. In contrast, the yields of VWC3 and VWC5 were quite high, 
1.6 and 5.0 mg per liter TB medium, respectively. 
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Figure 3.12 CV2-VWC domains purified by HPLC column. M, protein markers; R, proteins in reducing conditions; 
NR, proteins in non-reducing conditions. 
 
Mass Spectroscopy results 
The identity of the VWC domains were characterized and determined by mass spectroscopy. 
The measured Mass value of the 4 VWC domains matched very well with their calculated 
values (Table 3.2). 
 
Table 3.2 Mass analysis of CV2-VWC2, 3, 4 and 5. 
Domain Mass measured Mass calculated 
VWC2 
VWC3 
VWC4 
VWC5 
7097.400 
8553.905 
8460.678 
8702.264 
7097.317 
8553.806 
8460.644 
8702.115 
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3.1.3 Preparation of 15N-labelled CV2-VWC1 and 15N13C-double labelled 
CV2-VWC1 
 
The expression plasmid pET32a [Trx-CV2-VWC1] was transformed into E. coli 
strain BL21 (DE3) and expressed in M9 minimal medium. 15N-VWC1 was generated 
using (15N) ammonium sulfate as the sole nitrogen source. For 15N13C-VWC1, the 
carbon source was (13C6-D-UL) glucose in the M9 minimal medium. We could get 
about 3.7 g (15N) and 2.91 g (15N13C) bacteria per liter M9 minimal medium. The 
labelled CV2-VWC1 was purified using the same methods as described above for the 
unlabelled protein. 
 
Consistent with our previous experiments with unlabelled CV2-VWC1, the fusion 
protein was expressed (Fig. 3.13 lane 2) and found primarily in the supernatant after 
sonication (lane 3). The majority of non-target proteins were removed by Ni-chelating 
chromatography (lane 4). After thrombin cleavage of the fusion protein, CV2-VWC1 
was efficiently disconnected from thioredoxin (lane 5). CV2-VWC1 was still mixed 
with thioredoxin after TMAE column (lane 6). Reverse phase HPLC can efficiently 
separate the CV2-VWC1 from thioredoxin (lane 7) and the active protein was purified 
with a BMP-2 affinity column (lane 8).  
 
 
 
 
 
 
Figure 3.13 Expression and purification of labelled CV2-VWC1 
subjected to SDS-PAGE. Lane M, marker; lane 1, uninduced 
bacteria; lane 2, induced bacteria; lane 3, supernatant after 
centrifugation of sonicated bacteria; lane 4, purified protein after 
Ni-chelating chromatography; lane 5, protein mixture after 
thrombin cleavage; lane 6, TMAE isolated Thioredoxin 
containing CV2-VWC1; lane 7, HPLC isolated CV2-VWC1; lane 
8, BMP-2 affinity column separated CV2-VWC1. 
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Mass spectroscopy 
Labelled CV2-VWC1 was characterized by mass spectroscopy. The result showed 
that about 99% of the CV2-VWC1 protein was labelled. We found that labelled 
CV2-VWC1 was not posttranslational modified, and the measured mass value of 
7702.205 KDa fitted very well with its theoretical value of 7702.055 KDa (Fig. 3.14). 
 
 
Figure 3.14 A: Mass spectroscopy analysis of N15C13-labelled CV2-VWC1. B: Deconvolution analysis of 
6-fold-charged ions with corresponding molecular weight. 
  
The yield of the labelled VWC1 was lower than the unlabelled ones (Table 3.3), and 
was likely due to the different E. coli strains used for the expression of the two 
proteins. Origami (DE3) is a modified cell strain of BL21. It is more efficient in 
facilitating correct disulfide bond formation of a fusion protein than BL21 (DE3). 
Thus it was not unexpected that the yield of the active 15N- or 15N13C- labelled 
CV2-VWC1 expressed in BL21 (DE3) was less than the unlabelled proteins, which 
were expressed in Origami (DE3) (Table 3.3). The labelled proteins were dialysed 
against 20 mM Na-phosphate, 20 mM NaCl, pH 6.6 plus 0.02% NaN3 and 
concentrated to 14 mg/ml (about 1-2 mM) for NMR measurement.  
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Table 3.3 Comparison of the yields of the labelled-VWC1 expressed in 13C-and 15N-containing M9 minimal 
medium and the unlabelled-VWC1 expressed in TB medium. 
 
 
 
3.1.4 Binding affinity and specificity of BMPs for CV2 and CV2-VWC domains 
 
The binding of CV2 to BMP-2/-7 and GDF-5 occurs via its N-terminal segment 
containing VWC1-5 (CV2-N) (78). However, which of the individual domains was 
required for binding was unknown. Now the binding of the individual CV2-VWC 
domains to representatives of three subfamilies of BMPs, i.e., BMP-2, BMP-7 and 
GDF-5 was determined by biosensor-based interaction analysis. Surprisingly, we 
found that CV2-VWC1 was the only one of the five existing VWC domains that is 
involved in binding. CV2-VWC1 bound to BMP-2, BMP-7 and GDF-5 with affinities 
similar to those of full-length CV2 and CV2-N (VWC1-5) (Table 3.4). In contrast, the 
VWC domains 2, 3, 4 and 5 did not show any measurable binding affinity for these 
ligands. BMP-2 bound to CV2 and CV2-VWC1 with high affinities, which was 
similar to the high affinity of BMP-2 for its type I receptor (30).  
 
 
Table 3.4 A Apparent KD of CV2 proteins to immobilized BMP-2. B Apparent KD of BMP-2, BMP-7 and GDF-5 to 
immobilized CV2 proteins.  
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When CV2-VWC1 was immobilized on the chip, the binding affinity of BMP-2 was 
about 4 nM, while binding affinity of CV2-VWC1 to immobilized BMP-2 was about 
22 nM (Fig. 3.15B). The difference could be explained by a speculation that the solute 
BMP-2 dimer binds simultaneously to two immobilized CV2-VWC1 on the chip (1:2 
interaction), which results in an enhanced affinity; while the separate VWC1 domains 
bind immobilized BMP-2 in a 1:1 interaction, leading to a lower affinity.  
 
A                                               B 
 
 
Figure 3.15 Binding affinity of BMP-2 for CV2-VWC1 was analyzed by Biacore. A, CV2-VWC1 was 
immobilized on the chip surface, with 25, 75, 100, 200 and 300 nM BMP-2 injected over the chip surface. B, 
BMP-2 was immobilized on the chip surface, with 20, 40, 60, 100, 200 and 300 nM CV2-VWC1injected over the 
chip.  
 
3.2 Identification of CV2 binding site for Chordin 
 
We previously found that CV2 and CV2-N (VWC1-5) could bind Chordin with the 
same binding affinity (Zhang, personal communication), suggesting that the CV2-N 
of CV2 is responsible for the binding with Chordin. In order to identify the exact 
binding sites, we expressed several fragments of CV2-N in SF9 cells. Fragments 
VWC1-4, VWC1-3, VWC4-5, VWC2-4 and VWC3-4 were expressed with a 
C-terminal thrombin cleavage site (LVPRGS) plus a 6×Histidine-tag in SF9 insect 
cells.  
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The 6 fragments of CV2-N were then purified with Ni2+/nitriloacetate/agarose and 
gel-filtration chromatography to more than 80% purity (Fig. 3.16) and used for the 
Biacore interaction analysis. 
 
 
As expected, Biacore analysis showed that fragments VWC1-4 and VWC1-3, which 
contained the VWC1, could bind to BMP-2 (Fig. 3.17A) with the same affinity as that 
of VWC1 alone. Interestingly, while VWC1-4 binds Chordin with a similar affinity as 
VWC1-5 (Fig. 3.17), VWC1-3 and VWC2-4 did not show any binding to Chordin.  
Other fragments, VWC4-5 and VWC3-4, could bind neither BMP-2 nor Chordin 
(Table 3.5). These results suggest that for Chordin binding VWC1 and VWC4 are 
required. In addition, the results presented here indicate that the negative results of 
BMP-binding for E. coli expressed VWC2, 3, 4 and 5 were not likely caused by 
incorrect folding of the proteins. 
 
Figure 3.17 Biacore analysis of to VWC1-4 (A) and VWC1-4M (B) to immobilized BMP-2 and chordin. 
Sensorgram showing overlay of the VWC/BMP-2 (grey) and VWC/Chordin (blue) interactions.  
 
 
Figure 3.16 Western blot analysis of the protein 
fragments expressed in SF9 cells. Protein fragments 
were analysed using 15 ul of supernatant samples from  
6 virus clones. The first antibody was an anti-his tag 
antibody. It was applied at a dilution of 1:1000. The 
secondary antibody was horseradish peroxidase 
(HRP)-labelled goat anti-mouse immunoglobulin G and 
was applied at a dilution of 1:7000. 
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All these results confirmed that only CV2-VWC1 could bind to BMPs and suggested 
that the VWC1 domain is not only involved in BMP-2 binding, but also participates in 
binding with Chordin. Furthermore, it is unknown whether VWC1 and VWC4 are 
sufficient for Chordin binding, since these results show that the contribution of VWC2 
and VWC3 can not be excluded. It is likely that the VWC4 domain forms a composite 
interface with VWC1 or VWC1-3 for Chordin binding. To test this idea, we generated 
a VWC1-4 insertion mutant (VWC1-4M) in which 12 random residues 
GSLVPRGSMLSG were inserted between VWC3 and VWC4.  
 
Table 3.5 Comparison of the binding of CV2 proteins for BMP-2 and Chordin. 
 
As expected, VWC1-4M could no longer bind to Chordin, whereas its BMP binding 
activity was retained (Table 3.5), indicating that the composite interface of CV2 for 
Chordin is successfully destroyed. Future experiments will be required to demonstrate 
the in vivo biological relevance of the CV2/Chordin interaction. This may offer a clue 
for the complicated pro- and anti-BMP activity of CV2. The Chordin 
binding-deficient mutant VWC1-4M will be a good candidate for such an experiment. 
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3.3 Crystallization of the BMP-2 /CV2-VWC1 binary complex 
3.3.1 Preparation of BMP-2 and CV2-VWC1 complex 
 
Our functional analysis of the CV2-VWC1/BMP-2 interaction indicated that 
CV2-VWC1 bound mainly to the knuckle epitope of BMP-2 (see later results). As two 
2 knuckle epitopes exist in the BMP-2 dimer, the binding stoichiometry of 
CV2-VWC1 and BMP-2 is very likely 2:1. We therefore mixed CV2-VWC1 and 
BMP-2 at a molar ratio of 2.4: 1 for the complex formation. More CV2-VWC1 was 
added to make sure that all the BMP dimers were occupied by the VWC1 molecules. 
BMP-2 was dissolved in H2O and diluted to 10 µM to ensure that BMP-2 would not 
precipitate in the final concentration under 5 µM during the mixture process. In 
parallel, CV2-VWC1 was dissolved in 10 mM HEPES, pH 7.4, and 1400 mM NaCl. 
After quickly mixing the two samples, the binary complex of BMP-2 and CV2-VWC1 
in the buffer of 10 mM HEPES, pH 7.4, 700 mM NaCl was applied for gel-filtration 
chromatography. 
 
Gel filtration chromatography  
As shown in Fig. 3.18A, the binary complex of BMP-2/CV2-VWC1 (peak 1) could be 
efficiently separated from the excess VWC1 (peak 2). The purity and identity of the 
proteins from the two peaks were characterized and determined by SDS-PAGE 
analysis (Fig. 3.18B). We noted that the VWC1 protein in fraction 26 and 27 showed 
3 bands, similar to what we usually saw in the VWC1 protein purified by the BMP-2 
affinity column. These VWC1 isomers have different mobility in the SDS-PAGE. 
They are unmodified proteins with the same molecular weight as characterized by 
Mass spectroscopy (see 3.1.1). 
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Figure 3.18 A Gel filtration chromatography of the binary complex of BMP-2 and CV2-VWC1. B SDS-PAGE 
analysis of the two peaks from FPLC. Lane 1-5: protein from fractions 26, 27, 28, 29 and 30; lane 6-7: protein 
from fractions 31 and 32.  
 
3.3.2 Crystallization of the binary complex of wt BMP-2/CV2-VWC1 and 
preliminary analysis of the native data 
 
Crystallization was performed according to the sitting and hanging Drop Vapor 
Diffusion method. The concentration of the complex BMP-2/CV2-VWC1 was 5-10 
mg/ml in 10 mM Hepes, pH 7.4 and 700 mM NaCl. 1 ul of protein sample was mixed 
with 1 ul of the screening reagents.   
 
Initial screening of the complex 
Initial crystallization trials were performed by the sitting drop vapor diffusion 
technique in Crystal Quick 96 well sitting drop plates. Hampton crystal screen kits 
Crystal screen 1, Crystal screen 2, SaltRx, Lite and Index of the Hampton research 
company (about 350 conditions) were used. 1 µl of protein (10 mg/ml) was mixed 
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with 1 µl of reservoir solution and this mixture was equilibrated against 100 µl of 
reservoir solution. The conditions with crystal formation were further optimized using 
24 well VDX plates. Conditions that gave rise to crystals are summarized in table 3.6. 
 
Table 3.6 Summary of conditions giving crystals for the BMP-2/CV2-VWC1 complex using Kits of 
Structure-Screen HR-I, Structure-Screen HR-II, Salt Screen, Index Screen and Lite Screen. 
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Crystal screen 1 and Crystal screen 2  
There were 12 conditions that could give rise to crystals from Crystal screen 1 and 2. 
Crystals growing in conditions of these two screening kits were small and 
needle-shaped or formed clusters composed of small needle crystals (Fig. 3.19). The 
12 crystallization conditions generating crystals were very similar. As shown in table 
3.6, the precipitant in most of the conditions contained different concentrations of 
PEG, explaining why crystals of BMP-2 and CV2-VWC1 complex from these 
crystallization conditions were similar in morphology. Crystals usually appeared in 
one to two days after the setting. 
 
Crystal screen Lite, Crystal Screen Salt, and Crystal screen Index 
Crystal screen Lite is similar to Crystal Screen I, but with the precipitant 
concentration halved. Only two conditions, #28 and #41, of the crystal screen Lite 
resulted in crysrals. The shape of the crystals from # 28 and # 41 were also similar to 
that from Crystal Screen I.  
 
#52 of Crystal Screen Salt was the only condition that gave crystals with different 
shapes. The crystals are needle-shaped, but larger than those from the other conditions 
(Fig. 3.19L). Precipitant of this condition was 2.4 M (NH4)2HPO4, instead of PEG 
solutions. Small needle shaped crystals could also be obtained from two 
crystallization conditions of Index screen.  
 
In summary, binary complex of BMP-2 /CV2-VWC1 could easily form needle-shaped 
crystals or clusters in different concentrations of PEG. Furthermore, one condition 
with 2.4 M (NH4)2HPO4 resulted in larger needle-shaped crystal without cluster 
formation. 
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Figure 3.19 Crystals of the CV2-VWC1/ BMP-2 binary complex obtained from initial screening. Crystallization 
conditions were 
A: 30% PEG 4000, 0.1 M Na Citrate, pH 5.6, 0.2 M NH4OAc (HR-I # 9)  
B: 30% PEG 8000, 0.1 M Na Cacodylate, pH 6.5, 0.2 M (NH4)2SO4 (HR-I # 15)                
C: 30% PEG 4000, 0.1 M Tris/HCl pH 8.5, 0.2 M NaOAc (HR-I # 22)   
D: 30% PEG 8000, 0.1 M Na Cacodylate, pH 6.5, 0.2 M NaOAc (HR-I # 28) 
E: 20% PEG 4000, 20% Isopropanol, 0.1 M Na Citrate, pH 5.6 (HR-I # 40) 
F: 20% PEG 4000, 10% Isopropanol, 0.1 M Na Hepes, pH 7.5 (HR-I # 41) 
G: 30% PEG 8000, 0.2 M (NH4)2SO4 (HR-I 30)    
H: 30% PEG 1500 (HR-I # 43) 
I: 2.0 M (NH4)2SO4, NaOAC pH 4.6 (HR-I # 47) 
J: 15% PEG 8000, 0.5 M Lithium Sulfate (HR-I # 50)     
K: 30% PEG2000, 0.1 M Na Acetate pH 4.6, 0.2 M (NH4)2SO4 (HR-II 13)    
L: 2.4 M (NH4)2HPO4, 0.1 M Tris/HCl, pH 8.5 (HR-Salt # 52)       
 
Crystal optimization 
Optimization of crystallization conditions was performed according to the hanging 
Drop Vapor Diffusion method using 24 well VDX Plates. 1 ul of the protein samples 
was mixed with 1 ul of the screening reagents. Crystallization was performed 
according to the initial screening results. Protein concentration, precipitant 
concentration, pH, salt concentration, and temperature were taken into account for 
optimization. 
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Crystal screening I # 9, # 15, # 22, # 28, # 40, crystal screening-index # 23 and Salt # 
52 from the 17 conditions that gave rise to crystals in initial screening, were chosen to 
be further optimized by the hanging drop diffusion method. Unfortunately, after 
optimization the crystals were still needle or silk shaped and the resolution of crystals 
from all these conditions was only about 8-10 Å (Fig. 3.20). One exception was the 
optimization of HR-Salt # 52 whose crystals were bigger than that in the initial screen 
and had a diffraction resolution of 5-6 Å. This condition was thus selected for further 
optimization.  
 
 
 
Figure 3.20 Crystals of BMP-2/CV2-VWC1 complex in the conditions of:  
A: 30% PEG4000, 0.1 M Tris/HCl pH 8.5, 0. 2 M NaOAc, 10% Glucose (HR-I # 22)         
B: 25% PEG 8000, 0.1 M NaCacodylate pH 6.0, 0.2 M NaOAc, 10% Sucrose (HR-I # 28) 
C: 30% PEG 4000, 0.1 M Nacitrate pH 5.6, 0.2 M (NH4)OAc (HR-I 9)   
D: 20% PEG 8000, 0.1 M NaCacodylate, pH 6.5, 0.2 M (NH4)2SO4 (HR-I 15)  
E: 25% PEG 4000, 20% Isoproponal, 0.2 M Nacitrate, 0.2 M (NH4)OAC, 12% Sucrose (HR-I 40)     
  
Optimization of HR-Salt # 52 
2.4 M (NH4)2HPO4, 0.1 M Tris/HCl, pH 8.5 was the basic composition of HR-Salt # 
52. In order to optimize the conditions for crystallization, protein concentration, 
precipitant concentration, pH, additives, cryoprotectants, buffer and temperature were 
considered. We could observe the difference between the crystal images when the 
concentration of precipitant (NH4)2HPO4 of HR-Salt # 52 varied from 2.4 M to 2.0 M. 
Rod-shaped crystals were obtained at room temperature in pH 8.5 when the 
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(NH4)2HPO4 concentration was between 2.2 -2.4 M. However, the third dimension of 
the crystals was very thin when the precipitant concentration was 2.4 M, and the 
crystals were silk-shaped when with a precipitant concentration of 2.0 M (Fig. 3.21 B 
and D). Interestingly, the crystals grow in 2.2 M (NH4)2HPO4 were mainly rod-shaped 
and the third dimension was relatively larger (Fig. 3.21 C). 
 
 
Figure 3.21 Crystal images of CV2-VWC1/BMP-2 complex at different precipitant concentrations. The conditions 
are as follows: 
A: Initial screening of CV2-VWC1/BMP-2 complex in 2.4 M (NH4)2HPO4, 0.1 M Tris/HCl, pH 8.5 
B: 2.4 M (NH4)2HPO4, 0.1 M Tris/HCl, pH 8.5 
C: 2.2 M (NH4)2HPO4, 0.1 M Tris/HCl, pH 8.5 
D: 2.0 M (NH4)2HPO4, 0.1 M Tris/HCl, pH 8.5 
 
Protein concentrations of 5, 8 and 10 mg/ml were then tested at room temperature. 5 
mg/ml appeared to be too low, since the crystals were small needle shaped at this 
protein concentration (Fig. 3.22A). In contrast, protein concentrations of 8 and 10 
mg/ml gave similar rod-shaped crystals mixed with needle-shaped crystals (Fig. 
3.22B and C). Considering most of the crystals were formed in 24 hours, which seems 
to be too fast, we selected the relatively lower protein concentration (8mg/ml) for 
further optimization.  
 
 
 
Figure 3.22 Crystal images of CV2-VWC1/BMP-2 complex from different protein concentrations of 5 (A), 8 (B) 
and 10 mg/ml(C) in 2.2 M (NH4)2HPO4, 0.1 M Tris/HCl pH 8.5, 10 % Glycerol reservoir solution. 
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When temperature was tested, we found that crystals grown at 4℃ were very small 
and needle-shaped, and no further growth was observed after 3 weeks. 
 
For pH optimization, using pH 8.5, 7.5 and 7.0, no significant differences for the 
shape of crystals was found. However, there were bigger club-shaped crystals at pH 
7.5.  
 
5-15 % of generally used cryoprotectants, Glucose, Sucrose and Glycerol were tested 
in the crystallization of the binary complex BMP-2/CV2-VWC1. We found that 
crystals were much smaller than in the original conditions without cryoprotectant 
when Glucose was added. The largest crystals were grown in conditions with sucrose 
added (Fig. 3.23C). Several other cryprotectants from a Hampton Kit (HR2-122) were 
also tested, but without significant improvement in crystal formation or their 
diffraction patterns. Finally, larger rod-shaped crystals with better diffraction were 
obtained in 5-10% glycerol and sucrose. 
 
 
 
Figure 3.23 Images of crystals of CV2-VWC1 /BMP-2 complex growing in different cryoprotectants in 2.2 M 
(NH4)2HPO4, 0.1 M Tris/HCl pH 7.5. (A) no cryoprotectant, (B) with 5 % Glycerol, (C) with 5 % Sucrose, (D) 
with 5 % Glucose. 
 
Data collection 
After optimization, crystals of native protein complex of BMP-2 and CV2-VWC1 
grew by mixing 1 ul of protein complex solution (8 mg/ml) with 1 ul 2.2 M 
(NH4)2HPO4, 0.1 M Tris pH7.5, 5-15% Sucrose or Glycerol and placing this mix over 
reservoir solution consisting of 2.2 M (NH4)2HPO4, 0.1 M Tris pH7.5, 5-15% Sucrose 
or Glycerol at room temperature. Crystals grew to final size within two weeks. About 
10% of the protein crystals could diffract to 3-4 Å, while the other crystals diffracted 
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to 4-6 Å.  
 
A complete native data set was acquired from wild-type BMP-2 and CV2-VWC1 on 
beamline X06SA at the SLS (Villigen, Switzerland). The data set from 180 1° frames 
consists of 17 136 unique reflections. The overall Rmerge was 10.5% in the resolution 
range 41.3–3.1 Å and the completeness was 100% (Table 3.7). The crystal belonged 
to the tetragonal space group P41 (or P43), with unit-cell parameters a = b = 82.4, c = 
140.9 Å. To solve the structure of the complex, molecular replacement was employed 
using the software Phaser (94) with the BMP-2 dimer (23) as the search template. A 
clear molecular- replacement solution (LLG = 2292 for both BMP-2 dimers, with 
RFZ = 10.5 and 4.7 and TFZ = 25.0 and 36.2 for the first and second BMP-2 molecule, 
respectively) allowed the placement of two BMP-2 dimers in the asymmetric unit and 
thus confirmed the tetragonal space group P41 as the correct enantiomer. However, 
electron density for the CV2-VWC1 domains was vastly incomplete and did not allow 
the building of a model of the full complex (Fig. 3.24). Using the NMR structures of a 
distantly related VWC domain of Procollagen IIA (90) as an additional search 
template was unsuccessful. 
 
Table 3.7 Data-collection and processing statistics for the native crystal (complex of BMP-2/CV2-VWC1). 
Values in parentheses are for the highest resolution shell. 
 
† Rmerge is defined as in Table 3.8 
 
Results 
  - 79 -         
 
Figure 3.24 Molecular replacement was initially used to perform phasing of the BMP-2/CV2-VWC1 complex. 
Although two BMP-2 dimers could be unambiguously placed in the asymmetric unit (only one is shown), only 
residual electron density was observed for the CV2-VWC1 molecule at the putative binding site as determined 
from mutagenesis data (54). One BMP-2 dimer is shown in ribbon representation, with part of an Fobs - Fcalc 
electron-density map contoured at 1.5σ shown around 15 Å of the putative CV2-VWC1-binding site. 
 
Additive screening  
Three Hampton Additive screening kits (72 conditions) were tested to improve the 
crystal quality. The basic composition of the buffer was 2.2 M (NH4)2HPO4, 0.1 M 
Tris, pH 7.5. 10% Sucrose was also added to keep the crystals in Cryoprotection. 1 ul 
of additive solution was first mixed with 4 ul reservoir solution, and then 1 ul of the 5 
ul mixture was mixed with 1 ul of protein sample. This 2 ul mixture was equilibrated 
against 1 ml of reservoir solution. In most conditions, proteins precipitated or gave 
rise to very thin needle-shaped crystals. However, larger rod-shaped crystals were 
obtained at room temperature in conditions with several additives. These include 3% 
w/v 1,6 Hexanediol, 0.01 M L-Cysteine, 0.01 M Spermidine, 0.01 M Hexaminecobalt 
Trichloride, 0.01 M Betaine monohydrate, 0.01 M Ammonium sulfate and 4% 2,2,2, 
Trifluoroethanol (TFE). The diffraction resolution from these crystals was about 3-4 
Å in conditions with additives of 0.01 M L-Cysteine and 0.01 M Ammonium Sulfate 
(Fig. 3.25). Generally, crystal quality was improved and about 40%-50% crystals with 
the two additives could diffract to 3-4 Å. The other 5 additives that resulted in larger 
crystals did not make any improvement on the diffraction resolution. 
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Figure 3.25 Crystal images of CV2-VWC1 /BMP-2 complex in 2.2 M (NH4)2HPO4, 0.1 M Tris/HCl, 10% Sucrose 
pH 7.5 with (A) 0.1 M (NH4)2SO4 and (B) 0.01 M L-Cystein.  
 
3.3.3 Crystallization of the Selenomethionine-labelled complex of BMP-2 and 
CV2-VWC1  
  
As the collected data from crystals of wild type BMP-2 and CV2-VWC1 did not 
allow building a model of the complex, the SeMet-driven MAD approach was 
therefore applied for experimental phasing. Since the number of native methionine 
residues was rather low when using the wild-type proteins (four methionines per 
BMP-2 dimer and none in CV2-VWC1), several residues in BMP-2 and CV2-VWC1 
were substituted in order to increase the number of methionines. In BMP-2 the 
substitutions Y41M and F91M were chosen owing to their position outside the BMP 
type I and type II receptor-binding epitopes (30). Interaction analysis using BIAcore 
showed that the binding affinity of BMP-2 (F41M,Y91M) to CV2-VWC1 is 
unaltered. 
 
As an alternative approach, SeMet labelling of CV2-VWC1 was also planned. 
However, since the wild-type sequence of CV2-VWC1 lacks methionines and no 
structural data for CV2-VWC1 were available, four polar residues were selected for 
exchange to methionine (Fig. 3.26). The single CV2-VWC1 mutants S28M, N33M, 
K39M and E41M could be expressed and purified in a similar manner as described for 
the wild-type protein. Their binding characteristics to BMP-2 were analysed by 
BIAcore, showing that all mutants exhibited wild-type binding affinity. 
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Figure 3.26 Amino acids sequence of CV2-VWC1 S28M, N33M, K39M and E41M. 4 amino acids were replaced 
with Methionines that were marked in red.  
 
Additionally, the CV2-VWC1 double mutants S28MN33M, N33ME41M and 
N33MK39M were prepared in order to further increase the number of methionines or 
to enable the use of unlabelled BMP-2 in the complex; however, only the variant 
CV2-VWC1 (N33M,K39M) could be prepared and isolated. Yield of CV2-VWC1 
(N33M,K39M) was very low, producing only 100-120 ug/g wet bacteria. The 
incorporation of SeMet was checked by Mass spectrometry, which suggested that the 
labelleding efficiency was about 90%-98% for the N33MK39M double mutant and 
the S28M single mutant (Fig. 3.27).  
 
Results 
 -82- 
 
 
Figure 3.27 Mass spectroscopy analysis of CV2-VWC1 mutants. A: CV2-VWC1 (N33M,K39M); B: CV2-VWC1 
(28M).  
 
The SeMet-labelled variants CV2-VWC1 (N33M,K39M) and SeMet 
CV2-VWC1(S28M) were used for complex preparation with SeMet BMP-2; however, 
only the complex SeMet BMP-2/SeMet CV2-VWC1(S28M) yielded diffracting 
crystals. The complexes SeMet BMP-2(Y41M,F91M)/CV2-VWC1 and SeMet 
BMP-2/SeMet CV2-VWC1(S28M) formed crystals similar to those of the wild-type 
proteins (Fig. 3.28).  
 
For data acquisition, SeMet BMP-2 (Y41M,F91M)/CV2-VWC1 crystals were grown 
at 294 K from 2.0 M (NH4)2HPO4, 0.1 M Tris/HCl pH 7.5, 8%(v/v) glycerol, 5%(w/v) 
sucrose, whereas SeMet BMP-2/SeMet CV2-VWC1(S28M) crystals were grown at 
294 K from 2.2 M (NH4)2HPO4, 0.1 M Tris/HCl pH 7.5, 10%(v/v) glycerol. 
Crystallization experiments were performed at a protein concentration of 8 mg/ml. 
Crystals grew reproducibly within 10 d to approximate dimensions of 200 × 500 × 
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500 um (Fig.3.28). 
 
 
 
 
Figure 3.28 Crystal images of the complex of SeMet BMP-2 and SeMet CV2-VWC1. A: Complex of SeMet 
BMP-2 (Y41M,Y91M) and wt CV2-VWC1. B: Complex of SeMet wt BMP-2 and SeMet VWC1(28M). C: 
Complex of SeMet wt BMP-2 and SeMet VWC1(33M39M). D: X-ray diffraction pattern from a crystal of SeMet 
BMP-2 (F41M,Y91M)/CV2-VWC1 complex. The diffraction limit of these crystals was about 2.7 Å. 
 
Three-wavelength data sets (inflection, peak and remote) were recorded from both 
crystals and processed using the software HKL-2000 (95) and CrystalClear (Rigaku) 
(Table 3.8). Despite the fact that crystals of the two complexes grew under identical 
conditions, crystals of the complex SeMet BMP-2 (Y41M,F91M)/CV2-VWC1 
belonged to space group I41, while crystals of the complex SeMet BMP-2/SeMet 
CV2-VWC1 (S28M) belonged to space group P41212 (or P43212). Trials to index the 
diffraction data of either SeMet BMP-2 (F41M,Y91M)/CV2-VWC1 or SeMet 
BMP-2/SeMet CV2-VWC1(S28M) in the ‘wrong’ space group failed, showing that 
two clear crystal forms exist despite the almost identical unit-cell parameters (Table 
3.9). Analysis of the data using the software SHARP/autoSHARP (96) showed the 
presence of seven out of eight Se sites in the asymmetric unit for crystals of the 
D 
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complex SeMet BMP-2 (Y41M,F91M)/CV2-VWC1 and six out of six Se sites for 
crystals of the complex SeMet BMP-2/SeMet CV2-VWC1 (S28M).  
 
Table 3.8 Data collection and processing statistics for SeMet-labelled crystals. Values in parentheses are for the 
highest resolution shell. 
 
 
 
Table3.9 Comparison of Rmerge values for the three data sets. Values in parentheses are for the highest resolution 
shell. All Rmerge values were obtained for the same resolution range of the peak data set and native data set. The 
respective resolution ranges are shown in Tables 3.8 and 3.9. The values in bold designate the data used for 
structure solution. Rmerge is defined as in Table 3.9. 
 
† Indexing not possible in this space group. 
 
In both cases almost all or all the expected Se positions were identified, confirming 
the presence of a binary complex consisting of a BMP-2 dimer and two CV2-VWC1 
domains in the asymmetric unit (Fig. 3.29), which is appropriate for a solvent content 
of around 63–65% (VM = 3.3–3.6 Å 3 Da-1) (97). The complex structure of BMP-2 and 
CV2-VWC1 was elucidated by Dr. Thomas D. Mueller. 
Results 
  - 85 -         
 
Figure 3.29 Harker sections of anomalous Pattersion maps of the complexes (a) 
BMP-2(F41M,Y91M)/CV2-VWC1 (only z = 0.5 shown) and (b) BMP-2/CV2-VWC1(S28M) (only z = 0.5 shown). 
The anomalous Patterson maps were produced with CNS, illustrating the data quality for phasing. SHELXD 
analysis of the data derived at peak wavelength suggest the presence of eight (c) and six (d) Se sites in the 
complexes BMP-2(F41M,Y91M)/CV2-VWC1 and BMP-2/CV2-VWC1(S28M), respectively, of which seven in 
BMP-2(F41M,Y91M)/CV2-VWC1 and all six in BMP-2/CV2-VWC1(S28M) could be refined with SHARP. 
 
The structures of the mutant proteins are now being determined in order to determine 
the molecular basis of the formation of different space groups by the two complexes. 
The final structures of the complexes of CV2-VWC1 bound to BMP-2 will provide 
the first insights into how BMP ligands are recognized by modulator proteins of the 
chordin family, of which CV2 is a member. 
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3.3.4 NMR analysis of CV2-VWC1 
 
We also analyzed the solution structure of CV2-VWC1. Preliminary analysis provided 
a nice NMR signal (Fig. 3.30). We would like to see how it is in the solution structure 
of CV2-VWC1, and to compare the structure of this domain alone in solution and that 
in complex and to see whether they have differences. The data sets for15N single and 
15N13C double-labelled proteins have been collected. The NMR analysis of labelled 
CV2-VWC1 is underway.  
 
Figure 3.30 Preliminary analysis of 15N-labelled CV2-VWC1 by NMR. 
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3.4  Structure of the binary complex of BMP-2 and CV2-VWC1 
3.4.1 Binding epitopes of BMP-2 for CV2-VWC1 
 
General description of the structure 
The complex consists of a single BMP-2 dimer and two molecules of the CV2-VWC1 
(Fig. 3.31). For BMP-2, every monomer contains residues Lys11-Arg114. The 
residues Leu1-Gly66 were included in the CV2-VWC1 structures.  
 
 
 
Figure 3.31 The structure of the BMP-2 and CV2-VWC1 complex. A, side view of the structure. BMP-2 dimer is 
shown in yellow and red, displaying the butterfly conformation. The two CV2-VWC1 domains are shown in green. 
B, a top view of the complex. The colour scheme is the same as in A.  
 
The butterfly-shaped BMP-2 homodimer in this structure has the same overall 
structure as that in the binary complex of BMP-2/BMPR-IAecd and the ternary 
complex of BMP-2/BMPR-IAecd/ActR-IIB (30, 32). Two CV2-VWC1 domains are 
located on two sides of the BMP-2 dimer and each VWC1 domain interacts with one 
β1 β2 
β3 
β4 
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monomer of BMP-2. There are no contacts between the VWC1 domains. The VWC1 
domain   manifests an N-terminal segment (residues Leu1 to Ser8), which we refer 
to as a clip, an N-termianl subdomain SD1 (Cys9–Lys42) and a C-termianl subdomain 
SD2 (Cys43–Gly66). Two disulfide-bonds within each subdomain maintain their 
rigidity, while a fifth disulfide-bond links the two subdomains. The N- and C- 
terminal subdomains are predominantly composed of a β-sheet configuration. Strands 
β1, β2, and β3, β4, respectively, form the N- and C-terminal antiparallel sheets (Fig. 
3.31A). The disulfide bonds of VWC1 are constructed as C1-C4, C2-C8, C3-C5, 
C6-C9 and C7-C10, which are consistent with that of Collagen IIA VWC domain (Fig. 
3.32). The concave surface formed by the N-terminal β-sheets contacts the convex 
surface of the BMP-2 fingers (knuckle epitope), while the C-terminal subdomain 
displays no contact with BMP-2 (Fig. 3.31). Notably, the N-terminal clip of VWC1, 
contacts the concave surface of the BMP-2 wrist epitope, constituted by residues from 
α3-helix of the BMP-2 monomer A, and the fingers of the monomer B, and the edge 
between the wrist and knuckle epitopes.  
 
 
 
Figure 3.32 Structure of the CV2-VWC1 domain, the 4 β strands are colored in lightblue and 5 disulfide bonds are 
marked.  
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Two distinct contact interfaces 
The total buried interface between VWC1 and BMP-2 is 1578 Å2, including 618 Å2 (2 
x 309 Å2) in the wrist epitopes and 960 Å2 (2 x 480 Å2) in the knuckle regions. These 
are not comparable to the type I and type II receptor interfaces, 2 x 1130 Å2 for 
BMP-2/BMPR-IAecd, 2 x 660 Å2 for BMP-7/ActR-IIecd and 2 x 774 Å2 for 
Act/ActR-IIBecd (30, 22).  
 
The binding sites for the CV2-VWC1 SD1 and clip overlap with both type I and type 
II receptor binding sites. The first binding contacts are formed by the clip that is 
bound predominantly through hydrophobic interactions. The hydrophobic side chain 
of Ile 2 of VWC1 inserts into a hydrophobic pocket on BMP-2 formed by Trp 28, Trp 
31, Val 63, Tyr 103 and Met 106 (Fig. 3.33A), mimicking a similar insertion of Phe 85 
of BMP receptors BMPR-IA into the hydrophobic cleft on BMP-2 (Fig. 3.33B) (30). 
This residue is thought to be a key determinant of all type I receptors. Although site 1 
overlaps only partially with type I receptor binding site, VWC1 is able to inhibit the 
binding of BMPR-IA to BMP-2, probably due to the abolishment of the Phe 85 
insertion. 
 
   
 
Figure 3.33 First ligand-binding interface of BMP-2 and CV2-VWC1 domain. A. part of the VWC1 clip binds to 
the wrist epitope of BMP-2. B. Phe 85 of BRIA inserts into the hydrophobic cleft of BMP-2. 
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The second binding site is formed by hydrophobic residues on the concave surface of 
VWC1 (Ala 7, Ile 18, Ile 21, Ile 27, Ala 36) that pack with hydrophobic BMP-2 
residues (Val 33, Ala 34, Pro 35 on finger 1, and Leu 90, Val 98, and Leu 90 on finger 
2) (Fig. 3.34A). In addition, the amide and carbonyl of Thr 5 and the amide of Ala 7 
of VWC1 form three hydrogen bonds with Asn 102 and Leu 100 of BMP-2, 
respectively (Fig. 3.34B). Although the buried surface in this binding site is smaller 
than those of type II receptor interfaces (480 Å2 versus 660-774 Å2), it overlaps 
almost perfectly with the core region of the type II receptor-binding sites, as seen in 
previous structures.  
 
 
Figure 3.34 Second Ligand-binding interface of BMP-2 and CV2-VWC1 domain. A. Open-book view of the 
hydrophobic interface of BMP-2 and CV2-VWC1 domain. B. The hydrogen bonds between BMP-2 Leu 100, Asn 
102 and CV2-VWC1 Ala 7, Thr 5 are shown by dashed lines.  
 
Because of these two interaction sites, CV2-VWC1 can inhibit BMP-2 from binding 
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to both type I and type II receptors. However, the functional epitopes and 
determinants, i.e., the sites and residues important for binding, are more sufficiently 
determined by mutagenesis (see below).  
 
3.4.2 Key interactions between CV2-VWC1 and BMP-2 
We generated an array of BMP-2 mutants in the wrist and knuckle epitope for type I 
and type II receptors to delimit binding epitopes for CV2 and CV2-VWC1 (Table 
3.7).  
 
Table 3.7 Mutational analysis of BMP-2 interaction with CV2 and CV2-VWC1. The binding affinities of wild-type 
BMP-2 (WT) for full-length CV2 and VWC domains are set to 1. Relative affinities show the influence of the 
mutations on binding. 
 
 
According to the structure of the ternary complex of BMP-2/BMPR-IA/ActR-IIB (32), 
six variants mutated in the wrist epitope and seven variants mutated in the knuckle 
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epitope (Table 3.7) were selected for analyzing the interaction of BMP-2 with CV2 
and CV2-VWC1 by Biacore analysis. The binding characteristics of the five wrist and 
three knuckle epitope mutants for different receptor ectodomains have been described 
elsewhere (34, 35). The additional mutants S88P, V98P and L100P bound to type II 
receptors with reduced affinities. The M106A mutant exhibited a reduced affinity for 
type I receptors. It has been shown that the corresponding mutant of M108A in activin 
behaved as an activin antagonist, possibly owing to its disrupted binding to type I 
receptor ActR-IB. The decrease in binding affinities between BMP-2 mutants and 
CV2/CV2-VWC1 reflect the influences of the amino acid substitutions in the wrist 
and knuckle epitope for binding.  
 
CV2-VWC1 showed similar decreased affinities to some of the BMP-2 variants like 
those for full-length CV2, suggesting that the epitopes of BMP-2 for the VWC1 
domain of CV2 are same to those of BMP-2 for the whole CV2 protein (Table 3.7). 
This result is consistet with the observation that CV2-VWC1 governs all binding 
affinity in CV2 (Table 3.4).  
 
Remarkably, the variant L100K exhibited a dramatic decreased affinity for 
CV2/CV2-VWC1 compared to that of L100P. This effect was even more pronounced 
for a L100K/N102D double mutant. When variants L100K and L100K/N102D were 
immobilized on the chip, the binding of CV2/CV2-VWC1 to these mutants was too 
weak to be measured. Taken together, these results demonstrate that CV2/CV2-VWC1 
binds to the BMP-2 knuckle epitope mainly by hydrophobic interactions and Leu 100 
of BMP-2 is a hot spot for CV2/CV2-VWC1 binding. The results of the mutational 
analysis are consistent with the crystal structure analysis showing that the two sites of 
BMP-2 are involved in binding.  
 
Our mutational analysis indicated that the binding epitope of BMP-2 for CV2 not only 
overlaps with the knuckle epitope, but also partially overlaps with the wrist epitope, as 
the wrist epitope mutant M106A exhibited 4.1- and 3.3-fold lower affintties to CV2 
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and CV2-VWC1, respectively (Table 3.7). These results fit perfectly with the structure 
of the BMP-2/VWC1 complex, which demonstrates that the clip and SD1 of VWC1 
bind to the knuckle and wrist epitopes respectively. Previous studies showed that the 
M106A mutant bound to the wrist epitope binding protein CHL2-VWC3 with reduced 
binding affinity, but bound to the knuckle epitope binding protein CHL2-VWC1 
normally. Interestingly, the affinity of M106A for Chordin VWC1 and VWC3 are also 
100- and 11-fold lower than the wt protein, respectively, even though the results of the 
mutational analysis clearly indicated that these two domains bind to the knuckle 
epitope of BMP-2 (54). These results suggest that besides CV2-VWC1, other VWC 
domains can also simultaneously bind both the knuckle and wrist epitopes of BMP-2.   
 
To define the contribution of the two subdomains for binding, we expressed the 
N-terminal subdomain with Cys 26 mutated to Serine, and thus no free cysteine 
remained in the protein. This construct (VWC1-SD2) has a similar affinity for BMP-2 
to that of the wt CV2-VWC1. This result suggests that the binding region of 
CV2-VWC1 is located in the N-terminal subdomain SD1. Similarly, to check the 
contribution of clip in binding, two truncation mutants were generated. The mutants 
VWC1-Δclip1 and VWC1-Δclip2 showed a 135- and 2400-fold lower affinity 
respectively than wt VWC1, indicating that the clip plays an important role in binding 
(Table 3.8).   
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Table 3.9 Geometry of hydrogen bonds in the BMP-2 and CV2-VWC1 interface. 
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In order to define the binding determinants of CV2-VWC1 for BMP-2, an array of 
CV2-VWC1 mutants were constructed according to the crystal structure (Fig. 3.35). 
The expression and purification procedure of the mutant proteins was the same as that 
for wt CV2-VWC1.  
 
 
 
Figure 3.35 SDS-PAGE analysis of purified CV2-VWC1 mutants. A: Lane 1 wt VWC1, lane 2 VWC1-Δclip1, lane 
3 I18A, lane 4 I18E, lane 5 I18R, lane 6 I 27A, lane 7 I27R and lane 8 36R under non-reducing conditions. B: lane 1 
wt VWC1, lane 2 I21A, lane 3 I21R, lane 4 L1A, lane 5 L1R, lane 6 I2A and lane 7 I2R under non-reducing 
conditions. 
  
The binding affinities of the CV2-VWC1 mutants for BMP-2 were analyzed by 
Biacore. As the SD1 binds to the BMP-2 knuckle epitope by hydrophobic bonds, 
which are formed mainly by Ile 18, Ile 21, Ile 27, Ala 36 of CV2-VWC1, these 
residues were thus mutated to Ala or Arg. The clip of CV2-VWC1 binds to the wrist 
epitope of BMP-2 by hydrogen bonds and hydrophobic interactions, in which Leu 1, 
Ile 2, Thr 3 and Thr 5 were mutated. Table 3.10 shows that no “hot” spot in the clip 
and SD1 was found for the binding. Most of the mutants have decreased affinities for 
BMP-2, partically the mutants I21A and I21R, which showed 10- and 40-fold 
decreased affinities, respectively, compared with wt CV2-VWC1. In the clip region, 
the I2A mutant showed a 6-fold lower affinity, highlighting the importance of the 
“knob-into-hole” interaction for binding. Thr3 contributes only marginally to binding, 
as the T3P mutant demonstrated only a 2.5-fold lower affinity. In contrast, Thr5 
contributes strongly to binding, since the clip mutant T5P in which the main chain 
hydrogen bonds were broken, exhibited about 21-fold lower affinity. The contribution 
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of the hydrogen-bond between the Ala7 amide and the BMP-2 Leu100 carbonyl could 
be estimated from the 20-fold difference in the binding affinities of the two truncation 
mutants Δclip1 and Δclip2, whose interaction only differs in this Hydrogen-bond. In 
summary, the binding in the SD1 involves several weak hydrophobic binding, and the 
residues Ile2, Thr 5 and Ala 7 of the clip contribute strongly to the binding to BMP-2. 
The clip residues and N-terminal β-sheets that form a concave surface work 
cooperatively for the binding, CV2-VWC1 thus binds to BMP-2 through both 
hydrogen bonds and hydrophobic interactions (Table 3.10). 
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As shown in Fig. 3.36, 200 nM CV2-VWC1 was able to completely inhibit the 
binding of 50 nM BMP-2 to immobilized BMPER-IA and ActR-IIB, similar to that of 
the complete CV2 protein. This result indicats that CV2 and CV2-VWC1 inhibite the 
binding of BMP-2 to both type I and type II receptors.  
 
    
 
Figure 3.36 Inhibition of the binding of BMP-2 to type I and with type II receptors by CV2 and CV2-VWC1 in 
Biacore. BMPR-IA (A) and ActR-IIBecd (B) were immobilized on the chip surface. 50 nM BMP-2 plus 150 nM 
CV2 (a) and 200 nM CV2-VWC1 (b) respectively, and 50 nM BMP-2 alone (c) were injected over the chip 
surface. 
 
3.5 Biological activity of CV2 and CV2-VWC1 in cell assay and in 
vivo 
 
3.5.1 Inhibition of BMP-2 signaling by CV2 and CV2-VWC1  
The inhibitory capability of CV2 and CV2-VWC1 was assayed in C2C12 cells. CV2 
inhibited alkaline phosphatase (ALP) activity induced by 10 nM BMP-2 with an IC50 
of 11 nM, in the same range as chordin (68). CV2-VWC1 was also able to inhibit 
BMP-2 signaling, but with a four times higher IC50 value (40 nM) (Fig. 3.37B). Using 
the Biacore interaction analysis, CV2-VWC1 bound to BMP-2 with the same affinity 
as CV2, and showed similar inhibitory activity with an in vitro receptor competition 
experiment (Fig. 3.36). Therefore, the different inhibitory capabilities of the 
CV2-VWC1 domain and full-length CV2, suggest that other parts of the CV2 
molecule play an inhibition role in the cell culture assay. 
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Figure 3.37 Inhibitory properties of CV2 and CV2-VWC1. Increasing doses of (A) CV2 and (B) CV2-VWC1 were 
applied to inhibit BMP-2 (10 nM)-induced alkaline phosphatase (ALP) activity in serum-starved C2C12 cells 
assay.  
  
The mutants of CV2-VWC1 show different inhibition activity to BMP-2, basically 
consistent with their binding affinity results to BMP-2. Wild-type CV2-VWC1 
exhibits an IC50 of 50 nM. VWC1SD2 that has only 1.6 fold lower affinity to BMP-2 
than wt CV2-VWC1 shows a four-fold lower IC50. All other variants, which have a 
reduced binding affinity for BMP-2 in vitro, can not (such as VWC1-Δclip1 and 
A36R) or only partially (such as I2A) inhibit BMP-2 induced ALP induction (Fig. 
3.38). 
 
Figure 3.38 Biological activity of CV2-VWC1 in C2C12 cells. Alkaline phosphatase expression was induced by 10 
nM BMP-2. Inhibition efficiency of CV2-VWC1 was determined by increasing doses of CV2-VWC1 protein 
added to the BMP-2.  
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3.5.2 BMP-2 variants that inhibit CV2 and CV2-VWC1 
In a previous study, a BMP-2 “receptor dead” mutant L51P was generated, which 
does not bind BMPR-IA but binds to type II receptors normally (35). It does not 
induce measurable ALP activity in C2C12 or ADTC5 cells and has no 
dominant-negative inhibitory effect. The L51P mutant binds normally to Noggin (35), 
chordin, CHL2 as well as CV2 (50). It can release inhibition of BMP-2-induced ALP 
activity by Noggin (33) and also by CV2 in a dose-dependent manner as shown in Fig. 
3.39. In the current study, five double or triple mutants of BMP-2 were generated, in 
which the knuckle epitope mutants A34D, L90A, V98P, L100P and L100K/N102D 
were introduced in addition to the L51P mutation. These mutants showed a 
dramatically reduced affinity for BMPR-IA, decreased affinities for BMPR-II, 
ActR-II, ActR-IIB, and normal or decreased affinities for CV2. The inhibition of 
BMP-2 activity by CV2 could be partially reversed to different extents by the five 
tested mutants. Fig. 3.39 shows that 25 nM L51P could completely relieve the 
inhibition of 10 nM BMP-2-induced ALP activity by CV2, and was also complete for 
the L51P/V98P double mutant, slightly weaker for L51P/L90A, significantly weaker 
for L51P/L100P and L51P/A34D, and completely lost for the L51P/L100P/K102D 
mutant. The release of the inhibition of BMP-2 activity by CV2 basically correlates 
with the binding affinities of the mutants to CV2 (Fig. 3.39). Taken together, these 
results open the perspective that BMP-2 mutants can be constructed, which 
specifically block single BMP modulator proteins. 
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Figure 3.39 Release of CV2-inhibited BMP-2 activities by BMP-2 mutants. Induction of alkaline phosphatase 
(ALP) by 10 nM BMP-2 in C2C12 cells was inhibited to 10% by 50 nM CV2. L51P and the combined double 
mutants do not induce ALP activity. The release of CV2-inhibited BMP-2 activity was determined at the indicated 
mutant concentrations. PKD, L51P/L100K/N102D-BMP-2. 
 
3.5.3 Biological activity of CV2-VWC1/CV2 in vivo 
In order to analyze the effects of CV2 on BMP signaling in vivo, 2 mutant constructs 
of CV2 were generated: a full length construct in which I21 was mutated to R and a 
construct based on CV2-CM in which I21 was mutated to R (78). These two 
constructs were injected into the zebrafish embryos. In contrast to wild type CV2, 
which can both dorsalize and ventralize (Fig. 3.40b,c,g,h), injection of CV2-I21R 
mRNA into the zebrafish embryos only led to a weakly ventralized phenotype (Fig. 
3.40d,g,h). This suggests that the BMP-2 antagonizing properties of CV2-VWC1 
correspond to the anti-BMP activity in the context of the whole CV2 protein. When 
we additionally introduced the mutation I21R, which strongly attenuates BMP-2 
binding of VWC1, into CV2-CM, a full rescue from dorsalization could be observed. 
Thus, the BMP-binding of VWC1 seems to be solely responsible for the anti-BMP 
activity of overexpressed CV2 in vivo, whereas the weak ventralizing activity 
(pro-BMP activity) of wt CV2 is very likely to be independent of BMP binding. One 
important conclusion of the in vivo experiments in zebrafish is therefore that the two 
contrary anti- and pro-BMP activities can be structurally separated to different 
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regions/domains of the full-length CV2. All CV2 in vivo experiments were performed 
in collaboration with the group of Dr. Matthias Hammerschmidt at the University of 
Freiburg. 
   
  
 
Figure 3.40 (a-h) Phenotypes of zebrafish embryos after mRNA injections. (a-f) Lateral views of 32 hpf embryos; 
arrows indicate dorsalized traits (loss of ventral tail fin/tail); arrowheads indicate ventralized traits (smaller head, 
expansion of ventral-most tissues). Injection of cv2-wt mRNA leads to both weakly dorsalized (C1 in b) or weakly 
ventralized (V1 in c) embryos, whereas injection of cleavage resistant construct cv2-CM mRNA causes strong 
dorsalization (C3 in e). Injections of mRNA of the mutants cv2-WT-I21R or cv2-CM-I21R result in weakly 
ventralized (d) or normal (f) embryos similar to those in c and a, respectively. (g) Graphical illustration of 
proportions of phenotypes generated on injection of different CV2 constructs. For classification, C5 (strong 
dorsalization) to V2 (strong ventralization) (78). (h) In situ hybridization of whole-mount 80% epiboly-stage 
embryos; animal pole views; dorsal, right. Arrows indicate the limits of dorso-lateral mesoderm marker tbx24 
(dark blue), which is expanded in dorsalized and reduced in ventralized embryos. 
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4. Discussion  
 
More and more Chordin-like proteins are found to play important roles in 
development. The abundance of von Willebrand factor type C domain in extracellular 
matrix proteins and their ability to bind a variety of TGF-β superfamily members 
suggests a conserved function for these repeats in regulating growth factor signaling 
in the extracellular matrix (52). The primary objective of this study was to determine 
the complex structure of VWC repeats and TGF-β superfamily members. We solved 
the first structure of a complex between a BMP and a VWC domain, and analyzed in 
detail their binding affinities and specificities. The structure determined for BMP-2 
bound to the VWC1 domain of CV2 provides new and interesting data, which in the 
future will augment an understanding of the cooperation of BMP-2 and CV2 during 
animal development. The methods for expression and purification of VWC domains 
provide a good example for the preparation of other VWC domain-containing 
proteins.  
 
4.1 Expression and purification of VWC domains 
 
VWC domains were prepared in insect cells or yeast cells in the previous studies (73, 
85). Our studies here showed that VWC domains with 4-5 disulfide bonds could be 
expressed in E. coli in an active form. Some of the VWC domains could be obtained 
with very high yield. For instance, we can get ~ 2 mg CV2-VWC1 and ~ 1 mg 
CV2-VWC5/g wet bacteria. CV2-VWC1 was very stable, which could keep in active 
at 30 °C for up to 4 weeks, thus this makes it suitable for the NMR solution structure 
analysis. However, for other VWC domains, i.e., CV2-VWC2 and VWC4, which 
could be isolated only in low yields from E. coli, their expression methods still need 
to be explored. Protein renaturation from inclusion bodies can be a choice, because 
VWC3 of CHL-2 has been expressed in this way with higher yield than that as native 
fusion proteins (Huang and Zhang, unpublished). However, the appropriate buffers for 
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renaturation of VWC domains still need to be investigated.  
 
Reverse phase HPLC was shown to be a good method for the VWC domains 
purification. During the purification, VWC domains are usually eluted by 26-27% 
acetonitrile, thus make them easily separated by reverse HPLC from other proteins 
such as thioredoxin, their dimer and multimer. Because of the common protein 
chemical features, reverse phase HPLC could be used as a good purification way for 
all VWC domains. 
 
4.2 Binding affinity and specificity of VWC domains 
 
BMP signaling is inhibited by modulator proteins through blocking type I and type II 
receptors. VWC domains are also able to prevent the binding of these two receptors to 
BMPs, which like Noggin that binds to the dimeric BMP-7 with very high affinity, 
occluding all four binding sites of the BMPs for the type I and type II receptors (45). 
Most of tested VWC domains such as Chordin VWC1, Chordin VWC3 and CHL-2 
VWC1 bind mainly to knuckle epitope of BMP-2, but CHL2-VWC3 was found to 
bind preferentially to the wrist epitope of BMP-2 (54). For CV2-VWC1, its 
N-terminal SD1 binds to knuckle epitope of BMP-2, but its clip binds to the wrist 
epitope of BMP-2. Moreover, even for the same epitope of BMP-2, different 
determinants are found for different VWC domains. 
 
The CV2-VWC1 domain is distinguished by the highest binding affinity for BMP-2 
among the few analyzed VWC domains of the Chordin family (54). Our data showed 
that CV2 recognize BMP-2 in a mechanism that differs from that of other Chordin 
family members such as Chordin and CHL2 in two aspects. First, CV2 binds to 
BMP-2 via VWC1 with high affinity, which is comparable with the cooperative 
binding of two VWC domains in complete Chordin or CHL2. Second, Tsg that 
participate both Chordin/BMP-2 and CHL-2/BMP-2 interaction does not participate in 
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CV2/BMP-2 interaction. Similar to full-length CV2, CV2-VWC1 alone could 
simultaneously block the binding of BMP-2 to both type I and type II receptors. The 
4-fold lower inhibitory capacity of CV2-VWC1 in cell assay compared to complete 
CV2 is probably caused by the lack of the steric hindrance from other parts of CV2.  
 
CV2-VWC1 binds to both knuckle and wrist epitopes of BMP-2 with an affinity of 20 
nM, which was similar to the high affinity of BMP-2 for its type I receptor (30). It is 
reported that other tested VWC domains bind to either BMPs knuckle or wrist epitope 
and their affinity for BMPs are only 100 nM-2000 nM (54). However, upon removal 
of the clip, the affinity of CV2-VWC1 for BMP-2 reduced more than 2000-fold. This 
suggests that the clip help to stabilize the binding of VWC1 to BMP-2. It also 
indicates that the oother VWC domains without clip might bind BMPs weakly, and 
the high affinity binding could be generated by cooperating with other parts. For 
instance, VWC1 and VWC3 of CHL-2 cooperatively form a 10 nM high affinity for 
BMP-2 (54). 
 
It will be interesting to know how the epitopes of other VWC domains for BMP 
binding are constructed, because there are more than 500 VWC domain-containing 
proteins and no clear homology is found for these domains in alignment beside the 
cysteine pattern. It is tempting to speculate that the numerous disulfide bonds of VWC 
domains provide a scaffold for the attachments of a diversity of loops that can 
generate different binding specificities similar to an immunoglobulin. In the conotoxin 
superfamily comprising many hundreds of members with a disulfide-rich core, a 
similar principle has been established (48, 98). 
 
Not all VWC domains have direct interaction with TGF-β superfamily members. 
Some of them are “silent” domains. The one VWC domain-containing protein CTGF 
can interact with BMPs, but only three of the four VWC domains of Chordin, two of 
the three VWCs of CHL2 and one of the five VWCs of CV2 can bind to BMPs (54, 
55,, 90). The binding affinities of VWC domains for ligands vary. For instance, CV2 
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binds to BMP-2 with high affinity and VWC1 governs all the binding of CV2 for 
BMPs. However, the VWC domains of Chordin and CHL-2 bind separately to BMPs 
with a low binding affinity and a high affinity could be only generated when they 
cooperate.  
 
The VWC domains are highly diverse except the conserved cysteine sequence 
according to the alignment results (Fig. 4.1). Therefore, it is difficult to predict 
anything about why VWC domains have different binding features to TGF-β 
superfamily numbers from the amino acid sequence.  
 
 
Figure 4.1 Alignment of the amino acid sequences of the VWC domains (CRD) of human Procollagen a2, mouse 
Chordin 1 to 4, zebrafish CV2 1 to 5, human CTGF and CYR61. Arrows indicate β-strands and lines indicate 
disulfide bonds as observed for the structure of the procollagen a2 VWC domain (from Prof. Sebald).  
 
The binding affinity and specificity of CV2-VWC1 domain for BMPs also open the 
perspective to generate BMP-2 mutants as specific antagonists for VWC domains (Fig. 
3.39). Studies showed that some of the VWC-containing proteins are involved in 
pathological process. For example, CTGF, which inhibits BMP signaling and 
promotes TGF-β activity via the binding of its VWC domain to BMP-4/TGF-β, has 
been shown playing a very important role in fibrotic disease (55). The multi-VWC 
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domain-containing protein Kielin could attenuate the pathology of renal fibrotic 
disease by enhancing BMP signaling while suppressing TGF-β activation (57, 58). 
The functions of the VWC-containing proteins in these processes must be properly 
regulated. The antagonist specifically for the defined VWCs might be used in the 
therapeutic intervention of the VWC-containing protein-related diseases.   
 
In this study, we found that the structure of CV2-VWC1 shares similarity with the 
VWC domain of Collagen IIA. They both contain two subdomains and the disulfide 
bond patterns are also identical. This implies that the structure of Collagen IIA VWC 
domain could be correctly folded. The reason for the absence of biological function 
for the Col IIA VWC is still not clear. Based on our structure of CV2-VWC1, the 
corresponding binding region of Col IIA to BMPs is largely inaccessible. BMP could 
bind only after a major rearrangement of the Col IIA VWC protein. This of course, 
would likely result in a low affinity. Study showed that the trimeric full-length Col IIA 
binds BMP-2 in vivo and in vitro (52, 91). These observations suggest that the 
intrinsic BMP affinity of single Col IIA VWC is low, and only when multiple VWC 
domains cooperate in full-length Col IIA, a high affinity is generated.  
 
The binding and receptor blocking mechanisms of Noggin, Follistatin, and CV2 share 
some clear analogies, although their overall structures are completely unrelated (45, 
50, 49). Noggin, Follistatin, and CV2-VWC1 differ vastly in size and architecture 
(Fig. 1.7 and Fig. 1.8), but all three modulator proteins and domains seem to interact 
with the ligand mainly via the type II receptor binding epitope. About 730 Å2 of 
surface area per molecule is buried in the knuckle epitope upon binding of Noggin to 
BMP-7, twice as much compared to the CV2-VWC1 SD1 binding to BMP-2. For 
Follistatin the complete type II receptor-binding site of Activin-A (Act-A) is covered 
by the domains FSD1 and FSD2 burying about 820 Å2 per molecule in the knuckle 
epitope. 
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Additionally, all structurally known modulator proteins block not only the type II 
receptor epitope but also the type I receptor epitope. The N-terminal domain of 
Follistatin binds in the wrist epitope of Activin-A, thereby inhibiting type I receptor 
binding (49). However, binding of Follistatin to BMPs might be different, as type I 
receptors and Follistatin were reported to bind simultaneously to BMP-4 (98). A clip 
in the N-terminal of Noggin, which is similar to the clip of CV2-VWC1, folds over 
finger 2 and binds in the BMP wrist epitope (45). The backbone Pro35–Ser38 of 
Noggin superimposes almost perfectly on the backbone of the corresponding residues 
Ile2–Thr5 in the clip of CV2-VWC1. Pro35 of Noggin makes a similar knob-into-hole 
interaction with BMP-7 as Ile2 of CV2-VWC1 with BMP-2. Noggin Ala36 and Ser38 
form hydrogen bonds to Asn83 and Lys127 of BMP-7, similar to those of Thr3 and 
Thr5 of the CV2-VWC1 clip in the interaction with BMP-2. Mutagenesis showed that 
substitution of Pro35 by Arg leads to a 7-fold lower affinity for BMP-7 (45). 
Furthermore, familiar Symphalangism (48) results from the heterozygous mutation 
P35S, confirming the importance of the N terminus of Noggin in vivo. 
 
4.3 VWC domains are multifunctional binding modules that exert 
multiple binding characteristics 
 
Current reports indicate that the VWC domains are versatile binding modules which 
exhibit multiple binding characteristics. They bind not only to BMPs, but also to other 
VWC domains, for instance, CV2-VWC1 binds to VWC2 of Chordin, and 
CHL2-VWC1 and VWC3 bind to Tsg, which does not contain the VWC domain but 
participates in the regulation of BMP functions by Chordin-like proteins (54). 
Recently, drosophila CV2 was found to associate with the BMP receptor Tkv, one 
BMP type I receptor (Mihaela Serpe et al. unpublished). These reports also confirm 
that VWC domain-containing proteins such as CV2 regulate BMPs signaling in 
multiple levels. They modify BMP signaling through interacting with ligands, and 
also contacting with other BMPs regulating proteins and the receptors. Therefore the 
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isolated BMP regulators may integrate into a network in extracellular levels. To date, 
it is still unclear if those “silent” VWC domains exert a purely structural role or if 
they interact with other not yet identified proteins. 
 
The binding epitope of CV2 for Chordin does not exist in one single domain, but is 
composed of two or more VWC domains that formed a composite interface. 
CV2-VWC1-4M could not bind to Chordin any more through successfully destroying 
this interface. It is interesting to see the in vivo effect of the Chordin binding 
deficiency mutant in which the same insertion as in CV2-VWC1-4M was introduced. 
The experiment is underway and the results might provide a clue for the pro-BMP 
activity of CV2. 
 
The structure of CV2-VWC1 domain manifests a two subdomain architecture tethered 
by a flexible linkage. This makes it possible that the N-terminal subdomain clip and 
SD1 bind to BMPs and SD2 contributes to the binding for Chordin.  
  
4.4 Mechanism of CV2 and CV2-VWC1 modulating BMP signaling  
 
Previous studies showed that CV2 could be a pro- or anti-BMP factor, depending on 
different contexts (78, 79, 81, 82). CV2 at excessive doses inhibits the 
BMP-dependent differentiation of osteoblast and chondrocyte in cell culture system 
(82). The transfection of 293T cells with a CV2 cDNA-containing plasmid reduced 
cellular response to BMP-4 in a BMP-responding luciferase reporter assay (81). These 
results are consistent with our observation that excessive doses of CV2 and 
CV2-VWC1 inhibited BMP-2-induced ALP activity, and the CV2-VWC1 variants 
that have reduced binding affinity to BMP-2 can not or only partially inhibit the 
BMP-2 induced ALP induction. Our results showed that variant CV2-I21R only cause 
weakly zebrafish embryos ventralization, which is consistent with in vivo anti-BMP 
activity of CV2. However, In vivo studies showed that CV2 is an essential pro-BMP 
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regulator during zebrafish gastrulation (78) and in mouse organogenesis (79).  
 
Loss-of-function analysis of CV2 in Xenopus embryos and knock-out mice yielded 
controversial results with that of gain-of-function studies in cell culture systems (78, 
79, 82). Loss-of-function basically showed CV2 play a promoting activity on BMP 
signaling, but gain-of-function studies showed both pro- and anti-BMP signaling 
activity. Although the mechanism of the in vivo pro-BMP activity of CV2 remains 
uncertain, our results in this study clearly showed that the anti- and pro-BMP activity 
is structurally separated to different regions/domains of the full-length CV2. The 
CV2-VWC1 alone, full-length CV2 and the uncleavable mutant CV2-CM exhibit the 
same binding affinity for BMP-2, which is competent with BMP receptors, result in 
their anti-BMP activity when they are at excessive doses. All the in vitro and in vivo 
anti-BMP activity of CV2 can be explained with this mechanism. To CV2-CM, it can 
bind to the proteoglycans in the extracellular matrix more effeciently than the cleaved 
wt CV2 (78). Therefore the anti-BMP signaling activity of uncleaved CV2 was 
increased compares to that of the wt CV2. Future study will have to determine if and 
how the uncleaved wt CV2 functions in vivo. 
 
As shown in our in vivo zebrafish experiment, the pro-BMP activity (weak 
ventralizing activity) of wt CV2 is very likely to be independent of BMP binding. The 
physical interaction of Chordin and CV2 is one of the biggest possibilities for its 
pro-BMP activity. Chordin mainly acts as an antagonist of BMP signaling by binding 
to BMPs via its VWC domains, but CV2 can inhibit its interaction with BMPs 
through binding to Chordin-VWC2 domain. Thus, CV2 acquires a pro-BMP activity 
in this way. It is possible that the cleaved wt CV2, which only weakly binds to the 
proteoglycans in the extracellular matrix, binds to chordin in vivo. Rentzsch et al. also 
reported that embryological epistasis analyses revealed a significant dependence of 
CV2 activity on Chordin function (78). They found that CV2 promotes BMP signaling 
by antagonizing Chordin, otherwise CV2 cannot display its full pro-BMP effect. This 
notion of CV2-Chordin competition was further supported by CV2 overexpression 
Discussion 
 - 110 -         
studies, showing that application of CV2-N can rescue the dorsalization caused by 
Chordin, whereas it cannot compensate for the loss of BMP signaling caused by 
knockdown of BMPs (78). It remains to be established whether the binding of CV2 to 
Chordin is relevant to its pro-BMP activity and how the stimulation of BMP signaling 
is achieved.  
 
According to previous results, CV2 functions as both a BMP antagonist and agonist 
depending on a number of factors, which include CV2 concentration, cell extracellular 
matrix, BMP modulator proteins that can interact with CV2 such as Chordin, and 
proteolytic processing and so on. In drosophila, the cleavage is not required to affect 
the CV2 function on BMP signaling, but dCV2 was found to interact with Tkv type I 
BMP receptor (Mihaela Serpe et al. unpublished), which has not been confirmed in 
vertebrate. The mechanisms that explain the function of CV2 still need to be explored. 
Additionally, the functions of the four other VWC domains and the long C-terminal of 
the large CV2 molecule are still unknown. Elucidation of their functions may help to 
explain the complicated anti- and pro-BMP activities of CV2 in early embryogenesis. 
In general, the mechanism of CV2 regulating BMP activity should not be explained 
simply by one or two factors.  
 
In this thesis, I described the expression of CV2-VWC domains. The interaction and 
biological analysis showed that CV2-VWC1 was responsible for binding of CV2 to 
BMPs. According to this result, VWC1 was used for preparation of the binary 
complex with BMP-2. After crystal structural analysis, we identified the binding 
determinants of CV2-VWC1 and BMP-2 by mutagenesis and interaction analysis. We 
provide the first structure of a complex between a VWC domain and a BMP ligand. 
Our results explain the mechanism by which CV2-VWC inhibit both the type I and 
type II receptor binding to BMP-2 and provide a paradigm for the large protein family 
which contains more than 80 VWC-containing proteins. Interestingly, CV2 binds to 
BMPs as well as BMP regulator Chordin. We found that the binding is not from one 
VWC domain, but a composite interface from at least two VWC domains. These 
Discussion 
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findings are helpful in elucidating the biological function of CV2 and other BMPs 
modulators in regulating BMP activity. 
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ActR-I   Activin Type I Receptor  
ActR-IB   Activin Type IB ReCeptor  
ActR-II    Activin Type II Receptor 
ActR-IIB   Activin Type IIB Receptor 
Alk    Activin receptor-like kinase  
ALP    Alkaline phosphatase   
ACN   Acetonitrile 
Amp    Ampicillin  
Ǻ     Angstrom 
BMP    Bone Morphogenetic Protein  
BMPR-IA   Bone Morphogenetic Protein Receptor Type IA 
BMPR-IB    Bone Morphogenetic Protein Receptor Type IB 
BMPR-II    Bone Morphogenetic Protein Receptor Type II 
bp      Basepare  
β-ME     β-Mercapoethanol 
CV2     Crossveinless 2 
CHD     Chordin 
CHL     Chordin like protein  
CR     Cysteine-rich 
Col IIA    Collagen IIA 
cDNA    complementary DNA 
Da     Dalton  
DNA     Deoxyribonucleic acid 
ddH2O    Double Distilled H2O 
DMEM    Dulbecco's modified Eagle's medium 
ecd     extracellular domain  
E.coli   Escherischia coli 
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FPLC     Fast Protein Liquid Chromatography 
GDF     Growth and Differentation Factor 
HPLC     High Performance Liquid Chromatography  
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LB     Luria Broth     
Mw     Molecular weight  
NMR     Nuclear magnetic resonance 
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RT     Room temperature 
red.     reduced 
rpm     Revolutions Per Minute 
SF9     Spodoptera frugiperda 
SDS     Sodium dodecyl sulphate  
SDS     Polyacrylamid-Gelelektrophorese SDS-PAGE 
TB     Terriffic Broth 
TβR-I     TGF-β Type I Receptor 
TβR-II     TGF-β Type II Receptor 
TFA     Trifluoroacetic acid 
TGF-β     Transforming Growth Factor β 
Trx     Thioredoxin 
VWC    von Willebrand factor type C domain 
wt      wild type 
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Bone morphogenetic proteins (BMPs) signaling regulates numerous processes of 
embryogenesis and organogenesis during vertebrate and invertebrate development. 
BMP function is regulated in the extracellular space by many modulator proteins, 
including those containing a von Willebrand factor type C (VWFC) domain. 
Crossveinless 2 is one of BMP extracellular modulator protein that contains 5 VWC 
domains. To data, the structural basis and the mechanism by which BMP is regulated 
by VWC containing proteins is poorly understood. 
 
This study describes the preparation, crystallization and structure determination of the 
binary complex consisting of BMP-2 and the first VWC domain of CV2. The complex 
consists of a single BMP-2 dimer and two CV2-VWC1 molecules. The VWC1 
structure manifests two subdomains architecture plus an N-termianl clip peptide. The 
binding sites for CV2-VWC1 clip and N-terminal subdomain SD1 overlap with both 
BMP type I and type II receptor binding sites.  
 
Mutagenesis/interaction studies enabled us to understand how affinity and specificity 
in the BMP-2/CV2-VWC1 are generated. One mutant that only contains clip and SD1 
has a similar affinity for BMP-2 to that of the wt CV2-VWC1, which suggests that the 
binding part of CV2-VWC1 locates in the N-terminal subdomain. The N-terminal clip 
plays an important role in binding, when the clip was deleted, CV2-VWC1 showed 
more than 2000-fold lower affinity than that of the wt VWC1. Residues on clip and 
N-terminal β-sheets of CV2-VWC1 that form concave surface work cooperatively for 
the binding to BMP-2, and the binding through both hydrogen bonds and hydrophobic 
interactions. It is also found that CV2 binds to BMPs as well as BMP regulator 
Chordin, and the binding is not from one VWC domain, but a composite interface 
from at least two VWC domains. 
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This study also shows the biological activity of CV2/CV2-VWC1 in vivo and in vitro. 
The blocking of BMP-2 wrist and knuckle epitopes by CV2-VWC1 can inhibit BMP 
signaling, therefore resulting to the CV2 anti-BMP activity. It is possible that the 
binding of CV2 to Chordin leading to its pro-BMP activity in vivo.  
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Signale von morphogenetischen Proteinen des Knochens („bone morphogenetic 
proteins“ im Englischen) (BMP) regulieren zahlreiche Prozesse der Embryogenese 
und Organbildung während der Entwicklung von Wirbeltieren und Wirbellosen. Die 
Funktion der BMP wird im Extrazellularraum durch viele Modulator-Proteine 
reguliert, solche, die eine von-Willebrand-Faktor-TypC (VWC)-Domäne enthalten, 
miteingeschlossen. Crossveinless2 (CV2) ist eines der extrazellulären 
BMP-Modulator-Proteine, das 5 VWC-Domänen enthält. Die strukturelle Grundlage 
und der Mechanismus, durch den BMP durch VWC beeinhaltende Proteine reguliert 
werden, ist bis heute schlecht verstanden. 
 
Diese Studie  beschreibt die Aufbereitung, Kristallisierung und Strukturbestimmung 
eines binären Komplexes, der aus BMP-2 und der ersten VWC-Domäne von CV2 
besteht. Der Komplex besteht besteht aus einem einzelnen BMP-2-Dimer und zwei 
CV2-VWC1-Molekülen. Die VWC1-Struktur zeigt eine Architektur von zwei 
Unterdomänen, die durch eine Bindung verknüpft sind. Die Bindungsstellen der 
N-terminalen CV2-VWC1-„Klammer” und der N-terminalen Unterdomäne decken 
sich mit den Bindungsstellen sowohl des BMP-Typ1- als auch des Typ2-Rezeptors. 
 
Mutagenese/Interaktions-Studien haben uns ermöglicht zu verstehen, wie Affinität 
und Spezifizität im BMP-2/CV2-VWC1-Komplex generiert wird. Eine Mutante, die 
nur die N-terminale Unterdomäne enthält, hat eine vergleichbare Affinität für BMP-2 
wie Wildtyp (wt) CV2-VWC1. Das deutet darauf hin, dass sich die Bindungsstelle 
von CV2-VWC1 in der N-terminalen Unterdomäne befindet. Die N-terminale 
„Klammer” spielt eine wichtige Rolle in der Bindung. Wurde die „Klammer“ entfernt, 
zeigte CV2-VWC1 eine 2000 fache geringere Affinität als wt CV2-VWC1. 
Aminosäureketten der N-terminalen „Klammer” und β-Faltblattstrukturen des 
CV2-VWC1 sind beide an der Bindung zu BMP-2 beteiligt und bilden eine konkave 
Oberfläche. CV2-VWC1 bindet an BMP-2 sowohl über 
Wasserstoffbrückenbindungen als auch durch hydrophobe Wechselwirkungen. 
Darüber hinaus wurde herausgefunden, dass CV2 an BMP und auch an den 
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BMP-Regulator Chordin bindet. Die Bindung wird nicht durch eine einzelne 
VWC-Domäne bewerkstelligt, sondern durch die zusammengesetzte Oberfläche von 
mindestens zwei VWC-Domänen. 
 
Diese Studie zeigt auch, die biologische Aktivität von CV2/CV2-VWC1 in vivo und 
in vitro. Eine Blockade der BMP-2-Hand- (wrist) und Fingergelenk- (knuckle) 
Epitope durch CV2-VWC1 kann die BMP-Signalwirkung verhindern, und deshalb 
eine CV2-anti-BMP-Aktivität zur Folge haben. Es ist ziemlich wahrscheinlich, dass 
die Bindung von CV2 an Chordin in vivo zu pro-BMP-Aktivität führt. 
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